<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.339725,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVUUU9XA1dRCAIPHQNACg4=","queueTime":0,"ttGuid":"9ffb1f24a8356519"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full">
<meta property="description" name="description" content="Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also of the ethical nature and issues relat...">
<meta property="og:title" name="title" content="Frontiers | The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study">
<meta property="og:description" name="description" content="Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also of the ethical nature and issues relat...">
<meta name="keywords" content="Genetics,cancer risk,Poland,population cancer screening,Cancer">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="13">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2023.1045817">
<meta name="citation_firstpage" content="1045817">
<meta name="citation_language" content="English">
<meta name="citation_title" content="The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study">
<meta name="citation_keywords" content="Genetics; cancer risk; Poland; population cancer screening; Cancer">
<meta name="citation_abstract" content="Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also of the ethical nature and issues related to variant interpretation. Nowadays, genetic cancer screening standards are different in every country and usually encompass only only individuals with a personal or family history of a relevant cancer. Here we performed a broad genetic screening for cancer-related rare germline variants on population data from the Thousand Polish Genomes database based on 1076 Polish unrelated individuals that underwent whole genome sequencing (WGS). We identified 19 551 rare variants in 806 genes related to the oncological diseases, among them 89% have been located in non-coding regions. The combined BRCA1/BRCA2 pathogenic/likely pathogenic according to ClinVar variants in the unselected population of 1076 Poles was 0.42%, corresponding to nine carriers. Altogether, on the population level, we found especially problematic the assessment of the pathogenicity of variants and the relation of ACMG guidelines to the population frequency. Some of the variants may be overinterpreted as disease-causing due to their rarity or lack of annotation in the databases. On the other hand, some relevant variants may have been overseen given that there is little pooled population whole genome data on oncology. Before population WGS screening will become a standard, further studies are needed to assess the frequency of the variants suspected to be pathogenic on the population level and with reporting of likely benign variants.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2023/01/20">
<meta name="citation_publication_date" content="2023/02/10">
<meta name="citation_author" content="Mroczek, Magdalena ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Liu, Jakub ">
<meta name="citation_author_institution" content="Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland">
<meta name="citation_author" content="Sypniewski, Mateusz ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Piekowski, Tadeusz ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Itrych, Bartosz ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Stojak, Joanna ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Pronobis-Szczylik, Bartosz ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Stpie, Maria ">
<meta name="citation_author_institution" content="Department of Sports Medicine, Doctoral School, Medical University of Lublin, Poland">
<meta name="citation_author" content="Kaja, Elbieta ">
<meta name="citation_author_institution" content="Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poland">
<meta name="citation_author" content="Dbrowski, Maciej ">
<meta name="citation_author_institution" content="MNM Bioscience Inc., United States">
<meta name="citation_author" content="Suchocki, Tomasz ">
<meta name="citation_author_institution" content="Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland">
<meta name="citation_author" content="Wojtaszewska, Marzena ">
<meta name="citation_author_institution" content="Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszw, Poland">
<meta name="citation_author" content="Zawadzki, Pawe ">
<meta name="citation_author_institution" content="MNM Bioscience Inc., United States">
<meta name="citation_author" content="Mach, Anna ">
<meta name="citation_author_institution" content="Department of Psychiatry, Medical University of Warsaw, Poland">
<meta name="citation_author" content="Sztromwasser, Pawe ">
<meta name="citation_author_institution" content="MNM Bioscience Inc., United States">
<meta name="citation_author" content="Krl, Zbigniew J. ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="citation_author" content="Szyda, Joanna ">
<meta name="citation_author_institution" content="Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland">
<meta name="citation_author" content="Dobosz, Paula ">
<meta name="citation_author_institution" content="Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland">
<meta name="dc.identifier" content="doi:10.3389/fonc.2023.1045817">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study","author":[{"@type":"Person","name":"Magdalena Mroczek","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]},{"@type":"Person","name":"Jakub Liu","affiliation":["Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland"]},{"@type":"Person","name":"Mateusz Sypniewski","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]},{"@type":"Person","name":"Tadeusz Piekowski","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland","Postgraduate Medical Education Center, Poland"]},{"@type":"Person","name":"Bartosz Itrych","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]},{"@type":"Person","name":"Joanna Stojak","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland","Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science, Poland"]},{"@type":"Person","name":"Bartosz Pronobis-Szczylik","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]},{"@type":"Person","name":"Maria Stpie","affiliation":["Department of Sports Medicine, Doctoral School, Medical University of Lublin, Poland"]},{"@type":"Person","name":"Elbieta Kaja","affiliation":["Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poland"]},{"@type":"Person","name":"Maciej Dbrowski","affiliation":["MNM Bioscience Inc., United States"]},{"@type":"Person","name":"Tomasz Suchocki","affiliation":["Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland","National Research Institute of Animal Production, Poland"]},{"@type":"Person","name":"Marzena Wojtaszewska","affiliation":["Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszw, Poland","Department of Haematology, Frederic Chopin Provincial Specialist Hospital, Poland"]},{"@type":"Person","name":"Pawe Zawadzki","affiliation":["MNM Bioscience Inc., United States"]},{"@type":"Person","name":"Anna Mach","affiliation":["Department of Psychiatry, Medical University of Warsaw, Poland"]},{"@type":"Person","name":"Pawe Sztromwasser","affiliation":["MNM Bioscience Inc., United States"]},{"@type":"Person","name":"Zbigniew J. Krl","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]},{"@type":"Person","name":"Joanna Szyda","affiliation":["Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland","National Research Institute of Animal Production, Poland"]},{"@type":"Person","name":"Paula Dobosz","affiliation":["Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland"]}],"datePublished":"2023-02-10","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2023","isPartOf":{"@type":"PublicationVolume","volumeNumber":"13","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2023.1045817"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 10 February 2023</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Cancer Genetics</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 13 - 2023 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2023.1045817">https://doi.org/10.3389/fonc.2023.1045817</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1434780" class="user-id-1434780"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1434780/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Magdalena Mroczek*&#x;&#x;&#x;">Magdalena Mroczek</a><sup>1*&#x2020;&#x2020;&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jakub Liu&#x;&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jakub Liu<sup>2&#x2020;&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Mateusz Sypniewski&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Mateusz Sypniewski<sup>1&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Tadeusz Pie&#x;kowski,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Tadeusz Pie&#x144;kowski<sup>1,3&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Bartosz Itrych&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Bartosz Itrych<sup>1&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Joanna Stojak,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Joanna Stojak<sup>1,4&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2082501" class="user-id-2082501"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2082501/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Bartosz Pronobis-Szczylik&#x;">Bartosz Pronobis-Szczylik</a><sup>1&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Maria St&#x;pie&#x;&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Maria St&#x119;pie&#x144;<sup>5&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2059509" class="user-id-2059509"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2059509/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="El&#xc;bieta Kaja&#x;">El&#x17c;bieta Kaja</a><sup>6&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2056992" class="user-id-2056992"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2056992/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Maciej D&#x;browski&#x;">Maciej D&#x105;browski</a><sup>7&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1121187" class="user-id-1121187"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1121187/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Tomasz Suchocki,&#x;">Tomasz Suchocki</a><sup>2,8&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Marzena Wojtaszewska,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Marzena Wojtaszewska<sup>9,10&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Pawe&#x; Zawadzki&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Pawe&#x142; Zawadzki<sup>7&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/989745" class="user-id-989745"><img class="pr5" src="https://loop.frontiersin.org/images/profile/989745/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Anna Mach&#x;">Anna Mach</a><sup>11&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1150796" class="user-id-1150796"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1150796/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Pawe&#x; Sztromwasser&#x;">Pawe&#x142; Sztromwasser</a><sup>7&#x2021;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zbigniew J. Kr&#xf;l&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zbigniew J. Kr&#xf3;l<sup>1&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/25754" class="user-id-25754"><img class="pr5" src="https://loop.frontiersin.org/images/profile/25754/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Joanna Szyda,&#x;">Joanna Szyda</a><sup>2,8&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/803713" class="user-id-803713"><img class="pr5" src="https://loop.frontiersin.org/images/profile/803713/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Paula Dobosz&#x;">Paula Dobosz</a><sup>1&#x2021;</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland</li><li><span><sup>2</sup></span>Biostatistics Group, Wroc&#x142;aw University of Environmental and Life Sciences, Wroc&#x142;aw, Poland</li><li><span><sup>3</sup></span>Postgraduate Medical Education Center, Warsaw, Poland</li><li><span><sup>4</sup></span>Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science, Jastrz&#x119;biec, Poland</li><li><span><sup>5</sup></span>Department of Sports Medicine, Doctoral School, Medical University of Lublin, Lublin, Poland</li><li><span><sup>6</sup></span>Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poznan, Poland</li><li><span><sup>7</sup></span>MNM Bioscience Inc., Cambridge, MA, United States</li><li><span><sup>8</sup></span>National Research Institute of Animal Production, Balice, Poland</li><li><span><sup>9</sup></span>Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzesz&#xf3;w, Rzesz&#xf3;w, Poland</li><li><span><sup>10</sup></span>Department of Haematology, Frederic Chopin Provincial Specialist Hospital, Rzesz&#xf3;w, Poland</li><li><span><sup>11</sup></span>Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland</li></ul><p><strong>Introduction:</strong> Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also regarding the ethical nature and issues related to variant interpretation. Nowadays, genetic cancer screening standards are different in every country and usually encompass only individuals with a personal or family history of relevant cancer.</p><p><strong>Methods:</strong> Here we performed a broad genetic screening for cancer-related rare germline variants on population data from the Thousand Polish Genomes database based on 1076 Polish unrelated individuals that underwent whole genome sequencing (WGS). </p><p><strong>Results:</strong> We identified 19 551 rare variants in 806 genes related to oncological diseases, among them 89% have been located in non-coding regions. The combined BRCA1/BRCA2 pathogenic/likely pathogenic according to ClinVar allele frequency in the unselected population of 1076 Poles was 0.42%, corresponding to nine carriers.</p><p><strong>Discussion:</strong> Altogether, on the population level, we found especially problematic the assessment of the pathogenicity of variants and the relation of ACMG guidelines to the population frequency. Some of the variants may be overinterpreted as disease-causing due to their rarity or lack of annotation in the databases. On the other hand, some relevant variants may have been overseen given that there is little pooled population whole genome data on oncology. Before population WGS screening will become a standard, further studies are needed to assess the frequency of the variants suspected to be pathogenic on the population level and with reporting of likely benign variants.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb15">It has been over 20 years since the very first version of the entire human genome was released. Not a long time afterward, the scientific community agreed that cancer is a disease of the genome. Today, although advanced sequencing methods are available at a reasonable price and the role of significant genetic variants localized along the whole genome is quite well defined, the clinical implementation of whole-genome sequencing (WGS) in diagnosis and treatment remains in its infancy. Tumor sequencing (somatic variants) can provide valuable information regarding treatment response and outcomes, however, cannot explain all cancer cases. Around 5-14% of all cancers are caused by germline (inherited) variants (<a href="#B1">1</a>). Usually, screening for germline variants related to oncological diseases encompasses only individuals with a personal or family history of relevant cancer. Here, we present the first whole-genome sequencing-based cancer population screening in the 1076 individuals from the Polish population.</p><p class="mb15">Cancer remains one of the major epidemiological challenges in Poland as the number of cancer deaths is increasing. In the last 50 years, it has risen by 2.5 times, and the survival rate is one of the lowest in Europe (<a href="#B2">2</a>). In Poland, women are affected most often by breast (22.9%), lung (9.9%), corpus uteri (7.0%), colon (5.9%), and ovary (4.3%) cancers (<a href="#B2">2</a>). Among Polish men, the most common are prostate (20.6%), lung (16.1%), colon (6.8%), and urinary bladder (6.4%) cancers (<a href="#B2">2</a>). The Polish population has an especially low cancer survival rate with over 10 percentage points lower than the 5-year survival rate of other European countries (<a href="#B3">3</a>). The most significant reasons for this are a too-late diagnosis caused by the lack of screening programs and poor access to the healthcare system (<a href="#B4">4</a>). Other characteristics of the Polish cancer-related genetic landscape are relative homogeneity and a strong influence of the founder effects (<a href="#B5">5</a>).</p><p class="mb15">The benefits of screening and preventive treatments for individuals with pathogenic cancer-related variants in different populations depend on the prevalence and penetrance of the mutation, the mortality associated with the disease, the age of the person screened, the potential effects of preventive measures on the risk of developing the disease, quality of life, and costs (<a href="#B6">6</a>).</p><p class="mb15">Some rare genetic variants have already been included in the populational screening, especially in isolated populations. Breast cancer prevention is one of the most broadly applied examples of population screening. The current screening strategy encompasses individuals with a personal or family history of relevant cancer and the criteria and screening for founder mutations in isolated populations, such as Ashkenazi Jews. In the Ashkenazi population, 3% of women carry one of the three ancient mutations: <i>BRCA1</i> 185delAG (c.68_69delAG), <i>BRCA1</i> 5382insC (c.5266dupC), or <i>BRCA2</i> 6174delT (c.5946delT) (<a href="#B7">7</a>, <a href="#B8">8</a>). In Poland breast cancer mutations <i>BRCA1</i> and <i>BRCA2</i> show a strong founder effect. The incidence of the founder breast cancer mutations in the unselected early-onset breast Polish population is around 6% (<a href="#B8">8</a>). Around 80%-90% of the <i>BRCA1</i> mutations in Polish cancer families can be explained by one of three founder mutations (5382insC, C61G and 4153delA) (<a href="#B6">6</a>). Although the identification of carriers of hereditary breast and ovarian cancer gene variants through family cancer history alone is suboptimal, population screening is still controversial. In one of the few population screening studies, it was shown that as many as 38 of 5908 women (0.64%) carried a clinically actionable pathogenic variant (<a href="#B9">9</a>). 42% of pathogenic variant carriers did not have a first-degree relative with breast or ovarian cancer and the family history was very often not informative (<a href="#B9">9</a>) Polish population has been examined mainly in the context of selected genes playing a role as a control for cancer patient studies. The population prevalence for combined founder <i>BRCA1</i> 5382insC and C61G variants in Poland was 0.25% (1/400) (<a href="#B10">10</a>). The following prevalence for <i>BRCA1</i> variants has been found: 0.17% for c.5266dupC, 0.1% for c.3819del5, and 0.08% for C61G variant. The testing strategy is suboptimal and detects only a fraction of <i>BRCA</i> pathogenic/likely pathogenic (P/LP) variants carriers (<a href="#B11">11</a>). In the Greater London Area, only 2.6% of total estimated carriers and 5.1% of detectable carriers have been identified in the general population with current NHS strategies (<a href="#B12">12</a>). Given the rising number of risk management options and the availability of new sequencing technologies, a future screening strategy requires an urgent discussion.</p><p class="mb0">The aim of this study is to investigate germline cancer-related gene variants on the population level in Poland, to assess the type of variation (i.e., point or structural), to compare the frequencies with the frequency of corresponding variants estimated for the non-Finnish European population (NFE), and to interpret their relevance in the context of the family history-based testing. Our study is an extension of the study presented in Kaja et&#xa0;al. (<a href="#B13">13</a>), however here we focus exclusively on the variants related to oncology, the frequency of these germline variants in a healthy genetically homogenous population and their potential significance on the clinical level. Further, we discuss the application of local genomic databases in oncology and the feasibility of populational cancer testing with WGS.</p><a id="h3" name="h3"></a><h2>Materials and methods</h2><h3>The cohort</h3><p class="mb15">The cohort was described in detail in Kaja et&#xa0;al., 2022 (<a href="#B13">13</a>). Briefly, the studied population was recruited through the project &#x201c;Search for genomic markers predicting the severity of the response to COVID- 19&#x201d; to the genetic predisposition to COVID-19 severity. Samples were collected from 1222 individuals of Polish origin (extended cohort), between April 2020 and April 2021. Among them 1076 were unrelated and did not suffer from any significant disease (core cohort), for a detailed cohort description see Kaja et&#xa0;al., 2022 (<a href="#B13">13</a>). Samples encompassed the whole territory of Poland. All participants, guardians, or parents of the participants under 18 years of age, provided informed consent before the collection of blood samples and filling in the clinical data form, which included a questionnaire about the country of origin and chronic diseases. All participants signed informed consent. The ethical approval for the study was obtained from the Ethics Committee of the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw (decision nr: 41/2020 from 3 April 2020 and 125/2020 from 1 July 2020). The database containing anonymized genetic variants is available and can be downloaded as a VCF file from <a href="https://naszegenomy.pl/">https://naszegenomy.pl/</a> after accepting the policy and filling in a short form.</p><p class="mb0">The core cohort consisted of 1076 unrelated individuals of Polish origin. The median age of participants was 45.4 (2&#x2013;99) years and there was a slight predominance of males (697 vs. 525). This is comparable to the median age in Poland. The core cohort characteristics are presented in <a href="#T1">Table&#xa0;1</a>. The patients have initially been recruited for the COVID studies, independent of their chronic disease status. The analysis of clinical data demonstrated that the most common chronic self-reported diseases in the survey were: hypertension (13.0%), cancer (4.6%), diabetes (4.0%), and hypothyroidism or Hashimoto&#x2019;s disease (3.0%). For hypertension (13 vs. 60.28% (<a href="#B14">14</a>)) and diabetes (4.0% vs. 6.97% (<a href="#B15">15</a>)) the self-reported prevalence was lower than those reported in the studies, whereas for cancer mostly incidence data are available. The types of tumours identified in individuals from the extended cohort of 1222 people are reported in <a href="#h10">Supplementary Table&#xa0;1</a>. Because access to the phenotypic information is restricted, we were not able to extract the cancer type and genetic variant information for the core cohort of 1076 only, due to technical reasons. The information on whether cancer has been confirmed pathologically was not collected. Also, the patient reported both benign and malignant tumours under the name &#x201c;cancer&#x201d;. No chronic disorders were reported by 86% of participants from the core cohort.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" name="table&#xa0;1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a><p><strong>Table&#xa0;1</strong> Sex and age characteristics of analyzed core cohort.</p></div><div class="DottedLine"></div><h3>Whole-genome sequencing and data processing</h3><p class="mb0">DNA was isolated from the patient&#x2019;s peripheral blood. The library has been prepared using a TruSeq DNA PCR-free kit (Illumina Inc., San Diego, CA, USA) and 550 bp inserts. Sequencing was performed on the Illumina NovaSeq 6000 platform with the following parameters: 150 bp paired-end reads, an average read depth of 35.26&#xd7;. The quality has been assessed with FastQC v0.11.7 and mapped to the GRCh38 human reference genome. Single-nucleotide variants and short indels have been identified with DeepVariant v0.8.0 and genotyped all together with GL nexus v1.2.6-0-g4d057dc. Multiallelic variant calls were decomposed into monoallelic and normalized groups using BCFtools v1.9 (<a href="#B16">16</a>). The variants have been annotated using the following resources: Ensembl Variant Effect Predictor v.107], including references to databases of genomic variants from ClinVar v. 20220624 and dbSNP build 151, variant population frequencies from the 1000 Genomes Project, and GnomAD v2.0.1 and v3.0, as well as pathogenicity scores, such as Polyphen-2, SIFT, DANN and CADD (<a href="#B13">13</a>). All gene coordinates were padded with variants in the 10 kb range at both ends of the genes.</p><h3>Cancer variant extraction and analysis</h3><p class="mb15">The variants associated with cancer were chosen based on the COSMIC database (Catalogue of Somatic Mutations in Cancer (<a href="#B17">17</a>)) and literature review based on the PubMed search (<a href="#h10">Supplementary Table&#xa0;2</a>). These variants were classified as having a high, moderate, or low impact based on Sequence Ontology terms. The annotation has been performed with a SNPEff software (for details see In-depth-NGS-Data-Analysis-Course). Furthermore, the variants were filtered to identify those with known pathogenicity in cancer, following the classification available in the ClinVar (version from 2022-06-24) database. The frequency of the variants in the Polish population (this study) was compared to the frequency estimated for the non-Finnish European (NFE EUR) population obtained from the gnomAD (accessed on 2022-07-02) database. NFE population is the most similar to the Polish population. The list of variants was filtered out for moderate and high impact as a first step, and then only variants annotated in gnomAD for the NFE were further considered. For better comparison, the differences in alternative allele frequencies (AF) between the Polish cohort and gnomAD NFE were expressed in terms of odds ratio defined as <math xmlns="http://www.w3.org/1998/Math/MathML" display="inline" id="im1"><mrow><mfrac><mrow><mi mathsize="10.5pt">A</mi><msub><mi mathsize="10.5pt">F</mi><mrow><mi mathsize="10.5pt">P</mi><mi mathsize="10.5pt">L</mi></mrow></msub></mrow><mrow><mi mathsize="10.5pt">A</mi><msub><mi mathsize="10.5pt">F</mi><mrow><mi mathsize="10.5pt">N</mi><mi mathsize="10.5pt">F</mi><mi mathsize="10.5pt">E</mi></mrow></msub></mrow></mfrac></mrow></math>where <i>AF<sub>PL</sub></i> is alternative allele frequency in polish cohort and <i>AF<sub>NFE</sub></i> is alternative allele frequency in gnomAD NFE. Statistical significance of odds ratios for each variant was estimated with Fisher&#x2019;s exact test and corrected for Bonferroni adjustments. The prevalence of carriers was counted as a ratio of positive samples to the total number of samples tested.</p><p class="mb15">To analyze genetic diversity AF from our database have been compared to exomes from gnomAD (gnomADe), genomes from gnomAD (gnomADg) and 1000 Genomes Project (1KGP) database (<a href="https://www.internationalgenome.org/">https://www.internationalgenome.org/</a>, accessed on 2023-01-13). The African (AFR), Admixed American (AMR), East Asian (EAS), South Asian (SAS) and European, gnomADe and gnomADg NFE and EUR for 1KGP, ancestries were considered. Variants were filtered according to Combined Annotation-Dependent Depletion CADD (<a href="https://cadd.gs.washington.edu/,CADD&gt;=20">https://cadd.gs.washington.edu/,CADD&gt;=20</a>), which is a deleteriousness measure.</p><p class="mb0">In the manuscript the conventional variant naming has been used. The HGVS nomenclature and genomic locations are available in the <a href="#h10">Supplementary Table&#xa0;3</a>.</p><a id="h4" name="h4"></a><h2>Results</h2><h3>The landscape of identified variants in the European context</h3><p class="mb0">Overall, 19551 variants related to oncological diseases have been identified in 806 different genes in the core cohort (<a href="#h10">Supplementary Table&#xa0;2</a>). Among them, 316 variants were of high impact and 9835 variants were moderate impact variants. Importantly, in our study 9739 (75.87%) of the 12836 rare variants defined by MAF&lt; 0.01 were classified as singletons (<a href="#f1">Figure&#xa0;1</a>). Among the variants, 1552 were located in introns and 17353 in exons. The MAF of variants of high, moderate and low impact (as assigned by VEP) was compared between NFE (gnomAD) and Polish populations (this study). The variant enrichment divided into medium and high frequency is presented in <a href="#f2">Figure&#xa0;2</a>. High-impact variant for <i>FANCC</i> had a significant OR (p&lt;0.05) in the Polish population. Moderate impact variants with the highest OR (p&lt;0.05) in the Polish population were: <i>NUTM2B, MUC4, NOTCH1, NUTM2B, USP6</i> (<a href="#T2">Table&#xa0;2</a>). Their functions and pathways they are involved in are presented in <a href="#T3">Table&#xa0;3</a>.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy">
  </picture>
</a><p><strong>Figure&#xa0;1</strong> Distribution of alternative allele frequencies of indels and SNPs related to oncological diseases.</p></div><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy">
  </picture>
</a><p><strong>Figure&#xa0;2</strong> Distribution variants related to cancers in the PL population based on their impact.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" name="table&#xa0;2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a><p><strong>Table&#xa0;2</strong> High and moderate impact variants with a significantly higher frequency in the PL population as compared to the gnomAD in NFE population.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE&#xa0;3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" name="table&#xa0;3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a><p><strong>Table&#xa0;3</strong> Protein's function, pathways and types of cancers related to the high and moderate impact variants with the highest OR.</p></div><div class="DottedLine"></div><h3>Polish population in the global context</h3><p class="mb15">To present variants related to oncology identified in our database in regard to global genetic diversity and other genetic and genomic databases, we compared the number of variants identified in the Polish population to different ancestries and from three databases. In the first step the analysis was performed for the <i>BRCA1/BRCA2</i> P/LP variants identified in the our database in the Polish population. In the context of 1KGP database, all these variants were unique across ancestries. The number of P/LP <i>BRCA1/BRCA2</i> variants shared according to gnomADg between Polish population (this study) and other ancestries presented as follows: NFE (n=5/7), AMR (n=3/7), AFR (n=2/7), EAS (n=1/7), SAS (n=1/7).</p><p class="mb0">In the second step, we analyzed the variants related to oncology in Poland in the broader perspective. Not to exclude common variants, but at the same time to use computational resources effectively, we analyzed the variants with CADD &gt; = 20 from the variants related o oncological diseases list. These included 8491 variants, among them 840 rare (MAF&lt;0.01) and 7651 common (MAF&gt;0.01). Among 8491 variants, 5647 were unique for Polish population (monomorphic) according to 1KGP database, 4392 according to gnomADe and 2315 according to gnomADg. The number of variants related to oncology shared between Polish cohort and particular ancestries is shown in <a href="#f3">Figure&#xa0;3</a>.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE&#xa0;3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy">
  </picture>
</a><p><strong>Figure&#xa0;3</strong> Variants shared between Polish population (this study) and different ancestries according to 1KGP, gnomADe and gnomADg. Legend: AFR- African, AMR- Admixed American, EAS-East Asian, SAS-South Asian and EUR (European-EUR for 1KGP and NFE-European non-Finnish for gnomADe and gnomADg).</p></div><div class="DottedLine"></div><h3>Variants in BRCA1/BRCA2</h3><p class="mb0">In the Polish population, 45 different rare variants were identified within the <i>BRCA1</i> gene and 72 in the <i>BRCA2</i>. Among them in <i>BRCA1</i> two were of a high impact, 30 of a moderate impact and 13 of a low impact. Among <i>BRCA2</i> five were of high impact, 46 of moderate impact and 21 of low impact. According to ClinVar three variants in <i>BRCA1</i> were classified as P/LP (c.5266dupC, 3819del5, and c.181T&gt;G (p.Cys61Gly)) and four variants in <i>BRCA2</i> (c.658_659delGT, c.1813dupA, c.5238dup and c.9371A&gt;T) were classified as P/LP. The <i>BRCA1/BRCA2</i> variants and their AF are shown in <a href="#h10">Supplementary Table&#xa0;4</a>. Altogether, the AF for the <i>BRCA1/BRCA2</i> P/LP variants according to ClinVar (<a href="#B18">18</a>) in the unselected populations of 1076 patients in a genetically homogenous Polish population was 0.42%. That means that we identified 9 P/LP <i>BRCA1/BRCA2</i> variants in the unselected Polish population. AF for the three pathogenic <i>BRCA1</i> founder variants was 0.23%. None of the <i>BRCA1/BRCA2</i> variants reached a statistically relevant higher allele frequency in the Polish population comparing to other European populations, suggesting that this kind of studies require a much larger cohort.</p><h3>Variants in non-BRCA1/BRCA2</h3><p class="mb0">Several genes in which the variants were identified, are related to hereditary cancer syndromes, such as <i>PALB2</i>, related to ovarian and breast cancer or <i>JAK2</i> (c.3323A&gt;G, p.Asn1108Ser) associated with lung adenocarcinoma, myeloproliferative neoplasm, breast invasive ductal carcinoma, polycythemia vera, and colon adenocarcinoma (<a href="#h10">Supplementary Table&#xa0;5</a>). <i>RAD51</i> protein product is involved in DNA repair and is altered in 0.65% of all cancers with lung adenocarcinoma, glioblastoma and glioblastoma multiforme (<a href="#B19">19</a>). Germline mutations in the <i>CDKN2A</i> strongly predispose to cutaneous melanoma (<a href="#B16">16</a>, <a href="#B20">20</a>). Although we identified a variant (c.194-3652G&gt;C) in the <i>CDKN2A</i> gene located only one bp distant from the pathogenic <i>CDKN2A</i> variant c.-34G&gt;T (<a href="#B21">21</a>, <a href="#B22">22</a>), after a thorough analysis the variant proved to be benign. Other variants reported as pathogenic/likely pathogenic/with conflicting interpretations of pathogenicity according to the ClinVar were located in the following genes: <i>MSH6</i> associated with Lynch Syndrome i.e. hereditary non-polyposis colorectal cancer (<a href="#B23">23</a>), <i>PIK3CB</i>, which is altered in 1.62% of all cancers such as colon adenocarcinoma, prostate adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma; <i>RPN1</i> altered in 0.19% of all cancers with high grade ovarian serous adenocarcinoma, colon adenocarcinoma, oesophageal adenocarcinoma, bladder urothelial carcinoma (<a href="#B24">24</a>). Although the variants in these genes have been described as enriched in cancer populations or considered pathogenic by expert panels, the evidence of variant pathogenicity is often reported in very small sample sizes comprising a few families in control and a diseased group and thus not being representative of the whole population.</p><h3>Phenotype correlation</h3><p class="mb0">Variants in 5 genes (<i>RPN1, CDKN2A, HRAS, PALB2, CBFA2T3</i>) have been identified in 32 individuals with tumor from the extended cohort and classified as pathogenic, likely pathogenic, and VUS <strong>(</strong><a href="#h10">Supplementary Table&#xa0;1</a>). Given the limited information on cancer in our study cohort, e.g., in 4 cases there is no information about the cancer type, it is difficult to correlate the cancer type with genetic variants. Variants in three genes (<i>RPN1, HRAS</i> and <i>PALB2</i>) were carried by several individuals with cancer in extended cohort. Ribophorin 1 (RPN1) is a major part of oligosaccharyltransferase complex, which takes part in the glycosylation process. <i>RPN1</i> is upregulated in breast cancer and has also been associated with several other cancers, such as high-grade ovarian serous adenocarcinoma, colon adenocarcinoma, oesophageal adenocarcinoma, and bladder urothelial carcinoma. As much as 7 out of 12 individuals from our cohort with cancer had a likely pathogenic variant on both alleles. Another recurrent variant was localized i<i>n HRAS</i> gene. HRAS is a known oncogene related to several different cancers, among them Costello syndrome, a rare condition predisposing to tumours in different parts of the body, epidermal tumours, head and neck cancer, bladder carcinoma, and with ovarian carcinoma patients, but was also identified in the healthy controls The variants frequency is not annotated in ClinVar so that it also requires further characterization on the populational level. The variant p.Ile1035Val in <i>PALB2</i>, associated with breast and ovarian cancers, was identified in two out of eight individuals with breast cancers and in one ovarian cancer person from the extended cohort. All these variants will be further followed up in the affected cohorts in Poland in further studies.</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">Oncology remains the major field that can benefit most from whole genome sequencing (<a href="#B25">25</a>). The first collection of over 350 cancer-related genes has been created, protein-coding genes to be more specific, with new genes being added over time (<a href="#B26">26</a>). More and more WGS is being performed in a variety of different populations, supporting the notion that WGS of different cohorts enhances the power to identify genetic associations (<a href="#B24">24</a>, <a href="#B27">27</a>&#x2013;<a href="#B30">30</a>). Recently, in light of rising population consciousness in terms of cancer population testing and with sinking costs of genetic testing it has been suggested that genetic testing should be offered on the population level. Cancer-susceptibility-gene (CSG) testing might shift from bespoke tests towards whole genome or whole exome analysis as a part of comprehensive population-wide programmes; incorporating such strategy into healthcare systems, with equitable access for the entire population, will be challenging. These issues should especially be discussed, together with variant-of-unknown-significance (VUS) interpretation, penetrance, and genetic counseling. The&#xa0;Thousand Polish Genomes database can find several applications in oncology and show benefits in comparison to the other genomic databases in the following areas: analysis of the intron variants, calculating a polygenic risk score (PRS) and being a reference database for the Polish studies on cancer patients.</p><p class="mb15">Traditionally, most of the studies were focused on the identification of cancer mutations solely in protein-coding genes, ignoring the remaining 99% of the genome. Gene panels can detect only mutations in 0.01 &#x2013; 0.10% of the genome, at best. The main reason for it was that a large proportion of early NGS-based studies was constrained to whole exome sequencing -&#xa0;a more cost-effective way of ascertaining large samples, as well as the fact that the functional annotation of the non-protein coding part of the genome has constantly been updated and thus made more informative (<a href="#B31">31</a>). In our study, 89% of the variants in cancer-related genes were identified in non-coding regions, although most of the database reported variants derived from the exons. Whole Genome Sequence (WGS) based analyses of thousands of genomes representing various cancer tissues revealed multiple cancer-driver events localised in non-coding regions of DNA such as promoters and introns, to name just a few. Such events include not only single nucleotide variations (SNV) but also small indels and larger structural changes (<a href="#B32">32</a>). There are already some attempts to better understand the function of the non-coding regions. For example, on the large UK Biobank sample a depletion rank has been applied to characterize the function and importance of the non-coding variants. Surprisingly, among the 1% of regions with the lowest DR, 13.0% were coding and 87.0% were non-coding (<a href="#B33">33</a>). This suggests the still not understood importance of non-coding regions.</p><p class="mb15">Rare variants in high/medium penetrance cancer-related genes, although significant, cannot explain the cancer genetic risk sufficiently. Some common variants (polymorphisms, SNPs with a frequency &gt;1%) may contribute to the individual high or moderate risks of developing cancer or alternatively may imply a lower risk of developing the malignant disease. Polygenic Risk Score (PRS) aggregates the effects of many genetic variants across the human genome into a single score, being an estimate of an individual&#x2019;s genetic liability to a trait or disease (<a href="#B34">34</a>). PRS can be useful in the prediction of the progression and recurrence of cancer, which allows improving the efficiency of population-level screening. Recent studies showed that common variants may sufficiently assess personal risk, at least for some types of cancers, such as breast, colon, lungs, thyroid and prostate (<a href="#B35">35</a>). For prostate cancer the combination of rare and common genetic variants has been reported to be the most efficient in the disease risk prediction (<a href="#B36">36</a>). Black et&#xa0;al. (<a href="#B37">37</a>) reported that a set of 72 SNPs PRS was predictive of prostate cancer and could be used to identify unaffected individuals at high risk of developing prostate cancer. In the case of breast cancer, Kapoor et&#xa0;al. (<a href="#B38">38</a>) highlighted that the lifetime risk of breast cancer associated with classical risk factors was greater for women with higher PRS. The estimation of genome wide PRS for breast and prostate cancers showed that having a high PRS led from 21% to 38% higher lifetime risk, and 4 to 9 years earlier disease onset. PRSs improved model calculations over age, sex and clinical risk and substantiated the application of PRS in population screening (<a href="#B39">39</a>). PRS may additionally play the role of biomarker or response markers for chemotherapy and be taken into consideration to reduce the costs of cancer screening (<a href="#B34">34</a>). There are also critical voices on the use of PRS, especially in a clinical setting. Before being introduced to the clinics, PRS must provide significant discrimination and be applicable in terms of early detection and prevention. One of the concerns regarding PRS is the fact that most analyses performed, are based on European populations and may not be generalizable to other (e.g., Asian) populations (<a href="#B40">40</a>). That is why understanding the cancer-related variants in the context of the country&#x2019;s population is crucial for the interpretation at the population level and later on in an individual context. Although the data gathered as part of this study do not include at the moment strictly cancer patients, they can, later on, serve as a population control for assessing PRS.</p><p class="mb15">To check the representation of the variants in genes related to oncology in the Polish cohorts, we compared them to the data of multiple ancestries from the global databases. For the <i>BRCA1/BRCA2</i> analysis, the pathogenic variants identified in this study for the Polish population were mostly shared with the NFE ancestry and just one common variant within the EAS and SAS ancestry was identified. As Polish <i>BRCA1/BRCA2</i> P/LP variants have a strong founder effect that is why as expected there are shared mainly with the European NFE population, which is the closest genetically. Most of these variants are not represented in the other ancestries. In the context of variants with a highest CADD (mostly common variants) located in the genes associated with cancer, when compared to the gomADg database, encompassing most of the variants, as many as 27% were monomorphic for Poles, but this was strongly dependent on the database. The result highlights the importance of creating a local database due to the fact that a large part of the variants related to oncological diseases is population specific and not shared not only between the various ancestries, but also between the same continent (PL vs. NFE). Moreover, the size of the database has a considerable meaning, while a low number of individuals can lead to bias. For example, 1KGP database encompasses around 3202 WGS individuals from different ancestries (<a href="#B41">41</a>), while gnomAD has aggregated 15.708 genomes and 125.748 exomes (<a href="#B42">42</a>). Although 1KGP database has several advantages, such as a broad representation of the human genetic variation among ancestries and inclusion of only healthy individuals, however considering only a small number of individuals may not properly illustrate the similarities and diversity between different ancestries in terms of germline variants related to cancer.</p><p class="mb15">The Thousand&#xa0;Polish Genomes database can be used as a reference database for germline cancer variants. To the best of our knowledge, this is the first study on the Polish population using a whole-genome sequencing approach for cancer predisposition screening. Previous studies focussed on selected genes and known founder mutation, although they have encompassed large cohorts, such as 16 229 healthy persons. The Thousand&#xa0;Polish Genomes database encompass also genetic modifiers and genetic biomarkers related to treatment outcomes. In Poland several projects targeted the discovery of new genes related to cancer and cancer susceptibility genes (<a href="#B43">43</a>, <a href="#B44">44</a>). The Thousand&#xa0;Polish Genomes database can provide population references for such studies. Also, recently it has been shown that it may be possible to construct germline variants from the discarded tumor sequencing reads (<a href="#B45">45</a>). The local population can help to validate such a result. One of the most relevant issues is in assessing variant pathogenicity. This is a challenge also for the variants already reported in ClinVar. For example, the variant in <i>PALB2</i> (c.3103A&gt;G (p.Ile1035Val)) gene reported as having conflicting interpretations of pathogenicity in ClinVar and suggested of being pathogenic in the literature (<a href="#B46">46</a>) was present in healthy individuals as well as in breast cancer individuals from the extended cohort Our study confirmed the presence of this <i>PALB2</i> (c.3103A&gt;G (p.Ile1035Val)) variant in the Polish core cohort in a very high AF (12.3%).</p><p class="mb0">Are we ready for population cancer screening using WGS? Given the sinking costs of sequencing technologies and the rising availability of prevention management alternatives, we are heading towards it. We identified nine P/LP variants in the <i>BRCA1/BRCA2</i> variants only in the unselected Polish population. However, especially on the individual level we are not able to interpret data reliably, for example in terms of PRS, and that is why we cannot make any prediction based on them. As a scientific and clinical community, we should further try to provide results of the negative association in databases like ClinVar, not only the positive ones. We should be aware of differences between populations, even within the same ethnicity group, and to be able to identify risk alleles we advocate for large cohorts. For now, cancer screening with WGS on a research basis in larger populations will show us how feasible the method could be in clinics.</p><a id="h6" name="h6"></a><h2>Data availability statement</h2><p class="mb0">The datasets presented in this study can be found in online repositories. The names of the repository can be found below: <a href="https://1000polishgenomes.com">https://1000polishgenomes.com</a>.</p><a id="h7" name="h7"></a><h2>Ethics statement</h2><p class="mb0">The studies involving human participants were reviewed and approved by the Ethics Committee of the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw (decision nr: 41/2020 from 3 April 2020 and 125/2020 from 1 July 2020). The patients/participants provided their written informed consent to participate in this study.</p><a id="h8" name="h8"></a><h2>Author contributions</h2><p class="mb15">Conceptualization, MM, PD, BI, JL. Formal analysis, MM, TS, JL. Data curation, TP, PD, PT, TS, JSt. Data generation, PD, PT, PZ, ZK, EK, MD, MW. Methodology, MM, MatS, TS, JSt, BP-S. Visualisation and writing&#x2014;original draft preparation, MM, JL, BI, JSz, BP-S, MarS. Writing&#x2014;reviewing and editing: JSz, PD, JSt, MD, BP-S, TP. Funding acquisition, ZK. Supervision: PD, JSz. All authors contributed to the article and approved the submitted version.</p><a id="h9" name="h9"></a><h2>Funding</h2><p class="mb15">This research was partially funded by the The National Centre for Research and Development project SZPITALE-JEDNOIMIENNE/2/2020 &#x201c;Development of an innovative diagnostic test to assess the course of COVID-19 and post-death complications with the aid of whole genome analysis".</p><a id="h10" name="h10"></a><h2>Acknowledgments</h2><p class="mb0">We thank the patients for consenting to take part in this study.</p><a id="h11" name="h11"></a><h2>Conflict of interest</h2><p class="mb15">Author PS and MD are employed by MNM Bioscience. Author MatS, EK and PD were employed by MNM Bioscience.</p><p class="mb0">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h12" name="h12"></a><h2>Publisher&#x2019;s note</h2><p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p><a id="h13" name="h13"></a><h2>Supplementary material</h2><p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1045817/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2023.1045817/full#supplementary-material</a></p><a id="h14" name="h14"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. <i>JAMA netw Open</i> (2022) 5(5):e2213070. doi: 10.1001/jamanetworkopen.2022.13070</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35594047/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jamanetworkopen.2022.13070" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TA+Yap&amp;author=A+Ashok&amp;author=J+Stoll&amp;author=E+Mauer&amp;author=VM+Nepomuceno&amp;author=KL+Blackwell&amp;publication_year=2022&amp;title=Prevalence%20of%20germline%20findings%20among%20tumors%20from%20cancer%20types%20lacking%20hereditary%20testing%20guidelines&amp;journal=JAMA+netw+Open&amp;volume=5&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Didkowska J, Wojciechowska U, Michalek IM, Caetano dos Santos FL. Cancer incidence and mortality in Poland in 2019. <i>Sci Rep</i> (2022) 12(1):10875.3. doi: 10.1038/s41598-022-14779-6</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41598-022-14779-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Didkowska&amp;author=U+Wojciechowska&amp;author=IM+Michalek&amp;author=FL+Caetano%20dos%20Santos&amp;publication_year=2022&amp;title=Cancer%20incidence%20and%20mortality%20in%20Poland%20in%202019&amp;journal=Sci+Rep&amp;volume=12&amp;pages=10875.3" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Burzy&#x144;ska M, Maniecka-Bry&#x142;a I, Pikala M. Trends of mortality due to breast cancer in Poland, 2000&#x2013;2016. <i>BMC Public Health</i> (2020) 20(1):120. doi: 10.1186/s12889-020-8256-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31996185/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12889-020-8256-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Burzy%C5%84ska&amp;author=I+Maniecka-Bry%C5%82a&amp;author=M+Pikala&amp;publication_year=2020&amp;title=Trends%20of%20mortality%20due%20to%20breast%20cancer%20in%20Poland%2C%202000%E2%80%932016&amp;journal=BMC+Public+Health&amp;volume=20&amp;pages=120" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. de Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999&#x2013;2007 by country and age: results of EUROCARE-5&#x2013;a population-based study. <i>Lancet Oncol</i> (2014) 15(1):23&#x2013;34. doi: 10.1016/S1470-2045(13)70546-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24314615/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1470-2045(13)70546-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+de%20Angelis&amp;author=M+Sant&amp;author=MP+Coleman&amp;author=S+Francisci&amp;author=P+Baili&amp;author=D+Pierannunzio&amp;publication_year=2014&amp;title=Cancer%20survival%20in%20Europe%201999%E2%80%932007%20by%20country%20and%20age%3A%20results%20of%20EUROCARE-5%E2%80%93a%20population-based%20study&amp;journal=Lancet+Oncol&amp;volume=15&amp;pages=23" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. G&#xf3;rski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in polish families with breast-ovarian cancer. <i>Am J Hum Genet</i> (2000) 66(6):1963&#x2013;8. doi: 10.1086/302922</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/10788334/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/302922" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+G%C3%B3rski&amp;author=T+Byrski&amp;author=T+Huzarski&amp;author=A+Jakubowska&amp;author=J+Menkiszak&amp;author=J+Gronwald&amp;publication_year=2000&amp;title=Founder%20mutations%20in%20the%20BRCA1%20gene%20in%20polish%20families%20with%20breast-ovarian%20cancer&amp;journal=Am+J+Hum+Genet&amp;volume=66&amp;pages=1963-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. G&#xf3;rski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder <i>BRCA1</i> mutations in polish breast cancer families. <i>Int J Cancer</i> (2004) 110(5):683&#x2013;6. doi: 10.1002/ijc.20162</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15146557/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.20162" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+G%C3%B3rski&amp;author=A+Jakubowska&amp;author=T+Huzarski&amp;author=T+Byrski&amp;author=J+Gronwald&amp;author=E+Grzybowska&amp;publication_year=2004&amp;title=A%20high%20proportion%20of%20founder%20BRCA1%20mutations%20in%20polish%20breast%20cancer%20families&amp;journal=Int+J+Cancer&amp;volume=110&amp;pages=683-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of <i>BRCA1</i> and <i>BRCA2</i> among ashkenazi jews. <i>New Engl J Med</i> (1997) 336(20):1401&#x2013;8. doi: 10.1056/NEJM199705153362001</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/9145676/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJM199705153362001" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JP+Struewing&amp;author=P+Hartge&amp;author=S+Wacholder&amp;author=SM+Baker&amp;author=M+Berlin&amp;author=M+McAdams&amp;publication_year=1997&amp;title=The%20risk%20of%20cancer%20associated%20with%20specific%20mutations%20of%20BRCA1%20and%20BRCA2%20among%20ashkenazi%20jews&amp;journal=New+Engl+J+Med&amp;volume=336&amp;pages=1401-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Lubi&#x144;ski J, G&#xf3;rski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fern&#xe1;ndez P, et al. BRCA1-positive breast cancers in young women from Poland. <i>Breast Cancer Res Treat</i> (2006) 99(1):71&#x2013;6. doi: 10.1007/s10549-006-9182-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16541315/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-006-9182-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Lubi%C5%84ski&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=T+Byrski&amp;author=J+Gronwald&amp;author=P+Serrano-Fern%C3%A1ndez&amp;publication_year=2006&amp;title=BRCA1-positive%20breast%20cancers%20in%20young%20women%20from%20Poland&amp;journal=Breast+Cancer+Res+Treat&amp;volume=99&amp;pages=71-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. <i>Genet Med</i> (2019) 21(4):913&#x2013;22. doi: 10.1038/s41436-018-0277-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30254378/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41436-018-0277-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SM+Rowley&amp;author=L+Mascarenhas&amp;author=L+Devereux&amp;author=N+Li&amp;author=KC+Amarasinghe&amp;author=M+Zethoven&amp;publication_year=2019&amp;title=Population-based%20genetic%20testing%20of%20asymptomatic%20women%20for%20breast%20and%20ovarian%20cancer%20susceptibility&amp;journal=Genet+Med&amp;volume=21&amp;pages=913-22" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B10" id="B10"></a> 10. Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, et al. Prevalence of the most frequent BRCA1 mutations in polish population. <i>J Appl Genet</i> (2011) 52(3):325&#x2013;30. doi: 10.1007/s13353-011-0040-6</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21503673/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s13353-011-0040-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Brozek&amp;author=C+Cybulska&amp;author=M+Ratajska&amp;author=M+Piatkowska&amp;author=A+Kluska&amp;author=A+Balabas&amp;publication_year=2011&amp;title=Prevalence%20of%20the%20most%20frequent%20BRCA1%20mutations%20in%20polish%20population&amp;journal=J+Appl+Genet&amp;volume=52&amp;pages=325-30" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B11" id="B11"></a> 11. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. <i>Nat Rev Clin Oncol</i> (2016) 13(1):41&#x2013;54. doi: 10.1038/nrclinonc.2015.173</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26483301/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrclinonc.2015.173" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;author=BM+Knoppers&amp;author=C+Turnbull&amp;publication_year=2016&amp;title=Population%20genetic%20testing%20for%20cancer%20susceptibility%3A%20founder%20mutations%20to%20genomes&amp;journal=Nat+Rev+Clin+Oncol&amp;volume=13&amp;pages=41" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B12" id="B12"></a> 12. Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, et al. Current detection rates and time-to-detection of all identifiable BRCA carriers in the greater London population. <i>J Med Genet</i> (2018) 55(8):538&#x2013;45. doi: 10.1136/jmedgenet-2017-105195</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29622727/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmedgenet-2017-105195" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Manchanda&amp;author=O+Blyuss&amp;author=F+Gaba&amp;author=VS+Gordeev&amp;author=C+Jacobs&amp;author=M+Burnell&amp;publication_year=2018&amp;title=Current%20detection%20rates%20and%20time-to-detection%20of%20all%20identifiable%20BRCA%20carriers%20in%20the%20greater%20London%20population&amp;journal=J+Med+Genet&amp;volume=55&amp;pages=538-45" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B13" id="B13"></a> 13. Kaja E, Lejman A, Sielski D, Sypniewski M, Gambin T, Dawidziuk M, et al. The thousand polish genomes&#x2013;a database of polish variant allele frequencies. <i>Int J Mol Sci</i> (2022) 23(9):4532. doi: 10.3390/ijms23094532</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35562925/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3390/ijms23094532" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Kaja&amp;author=A+Lejman&amp;author=D+Sielski&amp;author=M+Sypniewski&amp;author=T+Gambin&amp;author=M+Dawidziuk&amp;publication_year=2022&amp;title=The%20thousand%20polish%20genomes%E2%80%93a%20database%20of%20polish%20variant%20allele%20frequencies&amp;journal=Int+J+Mol+Sci&amp;volume=23&amp;pages=4532" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B14" id="B14"></a> 14. Szuba A, Martynowicz H, Zato&#x144;ska K, Ilow R, Regulska-Ilow B, R&#xf3;&#x17c;a&#x144;ska D, et al. Prevalence of hypertension in polish population of PURE Poland study. <i>J Health Inequal</i> (2016) 2:157&#x2013;62. doi: 10.5114/jhi.2016.65356</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.5114/jhi.2016.65356" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Szuba&amp;author=H+Martynowicz&amp;author=K+Zato%C5%84ska&amp;author=R+Ilow&amp;author=B+Regulska-Ilow&amp;author=D+R%C3%B3%C5%BCa%C5%84ska&amp;publication_year=2016&amp;title=Prevalence%20of%20hypertension%20in%20polish%20population%20of%20PURE%20Poland%20study&amp;journal=J+Health+Inequal&amp;volume=2&amp;pages=157-62" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B15" id="B15"></a> 15. Topor-Madry R, Wojtyniak B, Strojek K, Rutkowski D, Bogus&#x142;awski S, Ignaszewska-Wyrzykowska A, et al. Prevalence of diabetes in Poland: a combined analysis of national databases. <i>Diabetic Med</i> (2019) 36(10):1209&#x2013;16. doi: 10.1111/dme.13949</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30889281/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/dme.13949" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Topor-Madry&amp;author=B+Wojtyniak&amp;author=K+Strojek&amp;author=D+Rutkowski&amp;author=S+Bogus%C5%82awski&amp;author=A+Ignaszewska-Wyrzykowska&amp;publication_year=2019&amp;title=Prevalence%20of%20diabetes%20in%20Poland%3A%20a%20combined%20analysis%20of%20national%20databases&amp;journal=Diabetic+Med&amp;volume=36&amp;pages=1209-16" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B16" id="B16"></a> 16. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, et al. Mutation of the CDKN2A 5&#x2019; UTR creates an aberrant initiation codon and predisposes to melanoma. <i>Nat Genet</i> (1999) 21(1):128&#x2013;32. doi: 10.1038/5082</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/9916806/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/5082" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Liu&amp;author=D+Dilworth&amp;author=L+Gao&amp;author=J+Monzon&amp;author=A+Summers&amp;author=N+Lassam&amp;publication_year=1999&amp;title=Mutation%20of%20the%20CDKN2A%205%E2%80%99%20UTR%20creates%20an%20aberrant%20initiation%20codon%20and%20predisposes%20to%20melanoma&amp;journal=Nat+Genet&amp;volume=21&amp;pages=128-32" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B17" id="B17"></a> 17. COSMIC. The Catalogue Of Somatic Mutations In Cancer. <a href="https://cancer.sanger.ac.uk/cosmic">https://cancer.sanger.ac.uk/cosmic</a> (accessed on 01.03.2022).</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="http://scholar.google.com/scholar_lookup?title=COSMIC.%20The%20Catalogue%20Of%20Somatic%20Mutations%20In%20Cancer&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B18" id="B18"></a> 18. Szwiec M, Jakubowska A, G&#xf3;rski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. <i>Clin Genet</i> (2015) 87(3):288&#x2013;92. doi: 10.1111/cge.12360</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24528374/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12360" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Szwiec&amp;author=A+Jakubowska&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=J+Tomiczek-Szwiec&amp;author=J+Gronwald&amp;publication_year=2015&amp;title=Recurrent%20mutations%20of%20BRCA1%20and%20BRCA2%20in%20Poland%3A%20an%20update&amp;journal=Clin+Genet&amp;volume=87&amp;pages=288-92" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B19" id="B19"></a> 19. Andr&#xe9; F, Arnedos M, Baras AS, Baselga J, Bedard PL, Berger MF, et al. AACR project GENIE: Powering precision medicine through an international consortium. <i>Cancer Discovery</i> (2017) 7(8):818&#x2013;31. doi: 10.1158/2159-8290.CD-17-0151</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28572459/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/2159-8290.CD-17-0151" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Andr%C3%A9&amp;author=M+Arnedos&amp;author=AS+Baras&amp;author=J+Baselga&amp;author=PL+Bedard&amp;author=MF+Berger&amp;publication_year=2017&amp;title=AACR%20project%20GENIE%3A%20Powering%20precision%20medicine%20through%20an%20international%20consortium&amp;journal=Cancer+Discovery&amp;volume=7&amp;pages=818-31" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B20" id="B20"></a> 20. Harland M, Cust AE, Badenas C, Chang Y-M, Holland EA, Aguilera P, et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the united kingdom. <i>Hered Cancer Clin Pract</i> (2014) 12(1):20. doi: 10.1186/1897-4287-12-20</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25780468/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1897-4287-12-20" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Harland&amp;author=AE+Cust&amp;author=C+Badenas&amp;author=Y-M+Chang&amp;author=EA+Holland&amp;author=P+Aguilera&amp;publication_year=2014&amp;title=Prevalence%20and%20predictors%20of%20germline%20CDKN2A%20mutations%20for%20melanoma%20cases%20from%20Australia%2C%20Spain%20and%20the%20united%20kingdom&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=12&amp;pages=20" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B21" id="B21"></a> 21. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. <i>J Invest Dermatol</i> (2006) 126(3):660&#x2013;6. doi: 10.1038/sj.jid.5700094</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16397522/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.jid.5700094" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MJ+Eliason&amp;author=AA+Larson&amp;author=SR+Florell&amp;author=JJ+Zone&amp;author=LA+Cannon-Albright&amp;author=WE+Samlowski&amp;publication_year=2006&amp;title=Population-based%20prevalence%20of%20CDKN2A%20mutations%20in%20Utah%20melanoma%20families&amp;journal=J+Invest+Dermatol&amp;volume=126&amp;pages=660-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B22" id="B22"></a> 22. Puig S, Potrony M, Cuellar F, Puig-Butille JA, Carrera C, Aguilera P, et al. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. <i>Genet Med</i> (2016) 18(7):727&#x2013;36. doi: 10.1038/gim.2015.160</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26681309/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2015.160" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Puig&amp;author=M+Potrony&amp;author=F+Cuellar&amp;author=JA+Puig-Butille&amp;author=C+Carrera&amp;author=P+Aguilera&amp;publication_year=2016&amp;title=Characterization%20of%20individuals%20at%20high%20risk%20of%20developing%20melanoma%20in%20Latin%20America%3A%20bases%20for%20genetic%20counseling%20in%20melanoma&amp;journal=Genet+Med&amp;volume=18&amp;pages=727-36" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B23" id="B23"></a> 23. Lee S-C, Guo J-Y, Lim R, Soo R, Koay E, Salto-Tellez M, et al. Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in southeast Asia. <i>Clin Genet</i> (2005) 68(2):137&#x2013;45. doi: 10.1111/j.1399-0004.2005.00469.x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15996210/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1399-0004.2005.00469.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S-C+Lee&amp;author=J-Y+Guo&amp;author=R+Lim&amp;author=R+Soo&amp;author=E+Koay&amp;author=M+Salto-Tellez&amp;publication_year=2005&amp;title=Clinical%20and%20molecular%20characteristics%20of%20hereditary%20non-polyposis%20colorectal%20cancer%20families%20in%20southeast%20Asia&amp;journal=Clin+Genet&amp;volume=68&amp;pages=137-45" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B24" id="B24"></a> 24. Besenbacher S, Liu S, Izarzugaza JMG, Grove J, Belling K, Bork-Jensen J, et al. Novel variation and <i>de novo</i> mutation rates in population-wide <i>de novo</i> assembled Danish trios. <i>Nat Commun</i> (2015) 6(1):5969. doi: 10.1038/ncomms6969</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25597990/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ncomms6969" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Besenbacher&amp;author=S+Liu&amp;author=JMG+Izarzugaza&amp;author=J+Grove&amp;author=K+Belling&amp;author=J+Bork-Jensen&amp;publication_year=2015&amp;title=Novel%20variation%20and%20de%20novo%20mutation%20rates%20in%20population-wide%20de%20novo%20assembled%20Danish%20trios&amp;journal=Nat+Commun&amp;volume=6&amp;pages=5969" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B25" id="B25"></a> 25. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. <i>Nature</i> (2009) 458(7239):719&#x2013;24. doi: 10.1038/nature07943</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19360079/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature07943" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MR+Stratton&amp;author=PJ+Campbell&amp;author=PA+Futreal&amp;publication_year=2009&amp;title=The%20cancer%20genome&amp;journal=Nature&amp;volume=458&amp;pages=719-24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B26" id="B26"></a> 26. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. <i>Nat Rev Cancer</i> (2004) 4(3):177&#x2013;83. doi: 10.1038/nrc1299</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/14993899/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc1299" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PA+Futreal&amp;author=L+Coin&amp;author=M+Marshall&amp;author=T+Down&amp;author=T+Hubbard&amp;author=R+Wooster&amp;publication_year=2004&amp;title=A%20census%20of%20human%20cancer%20genes&amp;journal=Nat+Rev+Cancer&amp;volume=4&amp;pages=177-83" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B27" id="B27"></a> 27. Gilly A, Suveges D, Kuchenbaecker K, Pollard M, Southam L, Hatzikotoulas K, et al. Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits. <i>Nat Commun</i> (2018) 9(1):4674. doi: 10.1038/s41467-018-07070-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30405126/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41467-018-07070-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Gilly&amp;author=D+Suveges&amp;author=K+Kuchenbaecker&amp;author=M+Pollard&amp;author=L+Southam&amp;author=K+Hatzikotoulas&amp;publication_year=2018&amp;title=Cohort-wide%20deep%20whole%20genome%20sequencing%20and%20the%20allelic%20architecture%20of%20complex%20traits&amp;journal=Nat+Commun&amp;volume=9&amp;pages=4674" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B28" id="B28"></a> 28. Boomsma DI, Wijmenga C, Slagboom EP, Swertz MA, Karssen LC, Abdellaoui A, et al. The genome of the Netherlands: design, and project goals. <i>Eur J Hum Genet</i> (2014) 22(2):221&#x2013;7. doi: 10.1038/ejhg.2013.118</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23714750/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ejhg.2013.118" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DI+Boomsma&amp;author=C+Wijmenga&amp;author=EP+Slagboom&amp;author=MA+Swertz&amp;author=LC+Karssen&amp;author=A+Abdellaoui&amp;publication_year=2014&amp;title=The%20genome%20of%20the%20Netherlands%3A%20design%2C%20and%20project%20goals&amp;journal=Eur+J+Hum+Genet&amp;volume=22&amp;pages=221-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B29" id="B29"></a> 29. Telenti A, Pierce LCT, Biggs WH, di Iulio J, Wong EHM, Fabani MM, et al. Deep sequencing of 10,000 human genomes. <i>Proc Natl Acad Sci</i> (2016) 113(42):11901&#x2013;6. doi: 10.1073/pnas.1613365113</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27702888/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1073/pnas.1613365113" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Telenti&amp;author=LCT+Pierce&amp;author=WH+Biggs&amp;author=J+di%20Iulio&amp;author=EHM+Wong&amp;author=MM+Fabani&amp;publication_year=2016&amp;title=Deep%20sequencing%20of%2010%2C000%20human%20genomes&amp;journal=Proc+Natl+Acad+Sci&amp;volume=113&amp;pages=11901-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B30" id="B30"></a> 30. Gudbjartsson DF, Helgason H, Gudjonsson SA, Zink F, Oddson A, Gylfason A, et al. Large-Scale whole-genome sequencing of the icelandic population. <i>Nat Genet</i> (2015) 47(5):435&#x2013;44. doi: 10.1038/ng.3247</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25807286/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.3247" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DF+Gudbjartsson&amp;author=H+Helgason&amp;author=SA+Gudjonsson&amp;author=F+Zink&amp;author=A+Oddson&amp;author=A+Gylfason&amp;publication_year=2015&amp;title=Large-Scale%20whole-genome%20sequencing%20of%20the%20icelandic%20population&amp;journal=Nat+Genet&amp;volume=47&amp;pages=435-44" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B31" id="B31"></a> 31. Sun Y, Ruivenkamp CAL, Hoffer MJV, Vrijenhoek T, Kriek M, van Asperen CJ, et al. Next-generation diagnostics: Gene panel, exome, or whole genome? <i>Hum Mutat</i> (2015) 36(6):648&#x2013;55. doi: 10.1002/humu.22783</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25772376/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.22783" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Sun&amp;author=CAL+Ruivenkamp&amp;author=MJV+Hoffer&amp;author=T+Vrijenhoek&amp;author=M+Kriek&amp;author=CJ+van%20Asperen&amp;publication_year=2015&amp;title=Next-generation%20diagnostics%3A%20Gene%20panel%2C%20exome%2C%20or%20whole%20genome&amp;journal=Hum+Mutat&amp;volume=36&amp;pages=648-55" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B32" id="B32"></a> 32. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. <i>Nat Rev Cancer</i> (2018) 18(1):5&#x2013;18. doi: 10.1038/nrc.2017.99</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29170536/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc.2017.99" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Anastasiadou&amp;author=LS+Jacob&amp;author=FJ+Slack&amp;publication_year=2018&amp;title=Non-coding%20RNA%20networks%20in%20cancer&amp;journal=Nat+Rev+Cancer&amp;volume=18&amp;pages=5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B33" id="B33"></a> 33. Halldorsson B, Eggertsson HP, Moore KHS, Hauswedell H, Eiriksson O, Ulfarsson MO, et al. The sequences of 150,119 genomes in the UK biobank. <i>Nature</i> (2022) 607(7920):732&#x2013;40. doi: 10.1038/s41586-022-04965-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/35859178/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41586-022-04965-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Halldorsson&amp;author=HP+Eggertsson&amp;author=KHS+Moore&amp;author=H+Hauswedell&amp;author=O+Eiriksson&amp;author=MO+Ulfarsson&amp;publication_year=2022&amp;title=The%20sequences%20of%20150%2C119%20genomes%20in%20the%20UK%20biobank&amp;journal=Nature&amp;volume=607&amp;pages=732-40" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B34" id="B34"></a> 34. Sud A, Turnbull C, Houlston R. Will polygenic risk scores for cancer ever be clinically useful? <i>NPJ Precis Onc</i> (2021) 5:40. doi: 10.1038/s41698-021-00176-1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41698-021-00176-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Sud&amp;author=C+Turnbull&amp;author=R+Houlston&amp;publication_year=2021&amp;title=Will%20polygenic%20risk%20scores%20for%20cancer%20ever%20be%20clinically%20useful&amp;journal=NPJ+Precis+Onc&amp;volume=5&amp;pages=40" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B35" id="B35"></a> 35. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. <i>Hum Mol Genet</i> (2019) 28(R2):R133&#x2013;42. doi: 10.1093/hmg/ddz187</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31363735/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/ddz187" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SA+Lambert&amp;author=G+Abraham&amp;author=M+Inouye&amp;publication_year=2019&amp;title=Towards%20clinical%20utility%20of%20polygenic%20risk%20scores&amp;journal=Hum+Mol+Genet&amp;volume=28&amp;pages=R133-42" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B36" id="B36"></a> 36. Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk. <i>Eur Urol</i> (2021) 80(2):134&#x2013;8. doi: 10.1016/j.eururo.2021.04.013</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33941403/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.eururo.2021.04.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BF+Darst&amp;author=X+Sheng&amp;author=RA+Eeles&amp;author=Z+Kote-Jarai&amp;author=DV+Conti&amp;author=CA+Haiman&amp;publication_year=2021&amp;title=Combined%20effect%20of%20a%20polygenic%20risk%20score%20and%20rare%20genetic%20variants%20on%20prostate%20cancer%20risk&amp;journal=Eur+Urol&amp;volume=80&amp;pages=134-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B37" id="B37"></a> 37. Black MH, Li S, LaDuca H, Lo MT, Chen J, Hoiness R, et al. Validation of a prostate cancer polygenic risk score. <i>Prostate</i> (2020) 80(15):1314&#x2013;21. doi: 10.1002/pros.24058</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33258481/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/pros.24058" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MH+Black&amp;author=S+Li&amp;author=H+LaDuca&amp;author=MT+Lo&amp;author=J+Chen&amp;author=R+Hoiness&amp;publication_year=2020&amp;title=Validation%20of%20a%20prostate%20cancer%20polygenic%20risk%20score&amp;journal=Prostate&amp;volume=80&amp;pages=1314-21" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B38" id="B38"></a> 38. Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindstr&#xf6;m S, Behrens S, et al. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. <i>J Natl Cancer Inst</i> (2021) 113(3):329&#x2013;37. doi: 10.1093/jnci/djaa056</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32359158/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/jnci/djaa056" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=PM+Kapoor&amp;author=N+Mavaddat&amp;author=PP+Choudhury&amp;author=AN+Wilcox&amp;author=S+Lindstr%C3%B6m&amp;author=S+Behrens&amp;publication_year=2021&amp;title=Combined%20associations%20of%20a%20polygenic%20risk%20score%20and%20classical%20risk%20factors%20with%20breast%20cancer%20risk&amp;journal=J+Natl+Cancer+Inst&amp;volume=113&amp;pages=329-37" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B39" id="B39"></a> 39. Mars N, Koskela JT, Ripatti P, Kiiskinen T, Havulinna AS, Lindbohm JV, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. <i>Nat Med</i> (2020) 26(4):549&#x2013;57. doi: 10.1038/s41591-020-0800-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32273609/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41591-020-0800-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Mars&amp;author=JT+Koskela&amp;author=P+Ripatti&amp;author=T+Kiiskinen&amp;author=AS+Havulinna&amp;author=JV+Lindbohm&amp;publication_year=2020&amp;title=Polygenic%20and%20clinical%20risk%20scores%20and%20their%20impact%20on%20age%20at%20onset%20and%20prediction%20of%20cardiometabolic%20diseases%20and%20common%20cancers&amp;journal=Nat+Med&amp;volume=26&amp;pages=549-57" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B40" id="B40"></a> 40. Cavazos TB, Witte JS. Inclusion of variants discovered from diverse populations improves polygenic risk score transferability. <i>HGG Adv</i> (2021) 2(1):100017. doi: 10.1016/j.xhgg.2020.100017</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33564748/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.xhgg.2020.100017" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TB+Cavazos&amp;author=JS+Witte&amp;publication_year=2021&amp;title=Inclusion%20of%20variants%20discovered%20from%20diverse%20populations%20improves%20polygenic%20risk%20score%20transferability&amp;journal=HGG+Adv&amp;volume=2&amp;pages=100017" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B41" id="B41"></a> 41. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-coverage whole-genome sequencing of the expanded 1000 genomes project cohort including 602 trios. <i>Cell</i> (2022) 185(18):3426&#x2013;3440.e19. doi: 10.1016/j.cell.2022.08.004</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/36055201/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cell.2022.08.004" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Byrska-Bishop&amp;author=US+Evani&amp;author=X+Zhao&amp;author=AO+Basile&amp;author=HJ+Abel&amp;author=AA+Regier&amp;publication_year=2022&amp;title=High-coverage%20whole-genome%20sequencing%20of%20the%20expanded%201000%20genomes%20project%20cohort%20including%20602%20trios&amp;journal=Cell&amp;volume=185&amp;pages=3426" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B42" id="B42"></a> 42. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> (2020) 581(7809):434&#x2013;43. doi: 10.1038/s41586-020-2308-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32461654/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41586-020-2308-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KJ+Karczewski&amp;author=LC+Francioli&amp;author=G+Tiao&amp;author=BB+Cummings&amp;author=J+Alf%C3%B6ldi&amp;author=Q+Wang&amp;publication_year=2020&amp;title=The%20mutational%20constraint%20spectrum%20quantified%20from%20variation%20in%20141%2C456%20humans&amp;journal=Nature&amp;volume=581&amp;pages=434-43" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B43" id="B43"></a> 43. Cybulski C, Carrot-Zhang J, Rivera B, Kashyap A, Woko&#x142;orczyk D, Giroux S, et al. Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nat Genet</i> (2015) 47(6):643&#x2013;6. doi: 10.1038/ng.3284</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25915596/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ng.3284" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=J+Carrot-Zhang&amp;author=B+Rivera&amp;author=A+Kashyap&amp;author=D+Woko%C5%82orczyk&amp;author=S+Giroux&amp;publication_year=2015&amp;title=Germline%20RECQL%20mutations%20are%20associated%20with%20breast%20cancer%20susceptibility&amp;journal=Nat+Genet&amp;volume=47&amp;pages=643-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B44" id="B44"></a> 44. Cybulski C, G&#xf3;rski B, Debniak T, Gliniewicz B, Mierzejewski M, Masoj&#x107; B, et al. NBS1 is a prostate cancer susceptibility gene. <i>Cancer Res</i> (2004) 64(4):1215&#x2013;9. doi: 10.1158/0008-5472.CAN-03-2502</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/14973119/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/0008-5472.CAN-03-2502" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=B+G%C3%B3rski&amp;author=T+Debniak&amp;author=B+Gliniewicz&amp;author=M+Mierzejewski&amp;author=B+Masoj%C4%87&amp;publication_year=2004&amp;title=NBS1%20is%20a%20prostate%20cancer%20susceptibility%20gene&amp;journal=Cancer+Res&amp;volume=64&amp;pages=1215-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B45" id="B45"></a> 45. Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N. Constructing germline research cohorts from the discarded reads of clinical tumor sequences. <i>Genome Med</i> (2021) 13(1):179. doi: 10.1186/s13073-021-00999-4</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34749793/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13073-021-00999-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Gusev&amp;author=S+Groha&amp;author=K+Taraszka&amp;author=YR+Semenov&amp;author=N+Zaitlen&amp;publication_year=2021&amp;title=Constructing%20germline%20research%20cohorts%20from%20the%20discarded%20reads%20of%20clinical%20tumor%20sequences&amp;journal=Genome+Med&amp;volume=13&amp;pages=179" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B46" id="B46"></a> 46. Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman A-R, et al. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. <i>Modern Pathol</i> (2016) 29(11):1381&#x2013;9. doi: 10.1038/modpathol.2016.135</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/modpathol.2016.135" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KL+Ring&amp;author=AS+Bruegl&amp;author=BA+Allen&amp;author=EP+Elkin&amp;author=N+Singh&amp;author=A-R+Hartman&amp;publication_year=2016&amp;title=Germline%20multi-gene%20hereditary%20cancer%20panel%20testing%20in%20an%20unselected%20endometrial%20cancer%20cohort&amp;journal=Modern+Pathol&amp;volume=29&amp;pages=1381-9" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> genetics, cancer risk, Poland, population cancer screening, cancer</p><p><span>Citation:</span> Mroczek M, Liu J, Sypniewski M, Pie&#x144;kowski T, Itrych B, Stojak J, Pronobis-Szczylik B, St&#x119;pie&#x144; M, Kaja E, D&#x105;browski M, Suchocki T, Wojtaszewska M, Zawadzki P, Mach A, Sztromwasser P, Kr&#xf3;l ZJ, Szyda J and Dobosz P (2023) The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study. <i>Front. Oncol.</i> 13:1045817. doi: 10.3389/fonc.2023.1045817</p><p id="timestamps"><span>Received:</span> 16 September 2022; <span>Accepted:</span> 20 January 2023;<br><span>Published:</span> 10 February 2023.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/563114">Elzbieta Pluciennik</a>, Medical University of Lodz, Poland</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/37853">Radka Kaneva</a>, Medical University Sofia, Bulgaria<br><a href="https://loop.frontiersin.org/people/118012">Andrea Degasperi</a>, University of Cambridge, United Kingdom</div><p><span>Copyright</span> &#xa9; 2023 Mroczek, Liu, Sypniewski, Pie&#x144;kowski, Itrych, Stojak, Pronobis-Szczylik, St&#x119;pie&#x144;, Kaja, D&#x105;browski, Suchocki, Wojtaszewska, Zawadzki, Mach, Sztromwasser, Kr&#xf3;l, Szyda and Dobosz. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Magdalena Mroczek, <a id="encmail">bS5tcm9jemVrODg4QGdtYWlsLmNvbQ==</a></p><p><span><sup>&#x2020;</sup></span>These authors have contributed equally to this work and share first authorship</p><p><span><sup>&#x2021;</sup>ORCID</span>: Magdalena Mroczek, <a href="https://orcid.org/0000-0002-8731-0540">orcid.org/0000-0002-8731-0540</a><br>Jakub Liu, <a href="https://orcid.org/0000-0003-4788-8417">orcid.org/0000-0003-4788-8417</a><br>Mateusz Sypniewski, <a href="https://orcid.org/0000-0002-0108-0255">orcid.org/0000-0002-0108-0255</a><br>Tadeusz Pie&#x144;kowski, <a href="https://orcid.org/0000-0002-0110-5950">orcid.org/0000-0002-0110-5950</a><br>Bartosz Itrych, <a href="https://orcid.org/0000-0002-2608-1289">orcid.org/0000-0002-2608-1289</a><br>Joanna Stojak, <a href="https://orcid.org/0000-0003-2423-5026">orcid.org/0000-0003-2423-5026</a><br>Bartosz Pronobis-Szczylik, <a href="https://orcid.org/0000-0001-5220-9859">orcid.org/0000-0001-5220-9859</a><br>Maria St&#x119;pie&#x144;, <a href="https://orcid.org/0000-0002-3377-4665">orcid.org/0000-0002-3377-4665</a><br>El&#x17c;bieta Kaja, <a href="https://orcid.org/0000-0003-1277-6140">orcid.org/0000-0003-1277-6140</a><br>Maciej D&#x105;browski, <a href="https://orcid.org/0000-0003-4150-3985">orcid.org/0000-0003-4150-3985</a><br>Tomasz Suchocki, <a href="https://orcid.org/0000-0002-8530-3486">orcid.org/0000-0002-8530-3486</a><br>Marzena Wojtaszewska, <a href="https://orcid.org/0000-0002-8979-2723">orcid.org/0000-0002-8979-2723</a><br>Pawe&#x142; Zawadzki, <a href="https://orcid.org/0000-0002-9032-2315">orcid.org/0000-0002-9032-2315</a><br>Anna Mach, <a href="https://orcid.org/0000-0002-2453-5320">orcid.org/0000-0002-2453-5320</a><br>Pawe&#x142; Sztromwasser, <a href="https://orcid.org/0000-0002-0661-8800">orcid.org/0000-0002-0661-8800</a><br>Zbigniew J. Kr&#xf3;l, <a href="https://orcid.org/0000-0003-3162-8813">orcid.org/0000-0003-3162-8813</a><br>Joanna Szyda, <a href="https://orcid.org/0000-0001-9688-0193">orcid.org/0000-0001-9688-0193</a><br>Paula Dobosz, <a href="https://orcid.org/0000-0002-5134-0975">orcid.org/0000-0002-5134-0975</a></p><div class="clear"></div></div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1045817" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3,546</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">831</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><!----><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1045817#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2023.1045817" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2023.1045817" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/563114/overview" data-event="editorInfo-a-elzbietaPluciennik" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">E</span><span class="notranslate">P</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Elzbieta  Pluciennik</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Medical University of Lodz, Poland</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/37853/overview" data-event="editorInfo-a-radkaKaneva" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">R</span><span class="notranslate">K</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Radka  Kaneva</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Medical University Sofia, Bulgaria</div></div></a><a href="https://loop.frontiersin.org/people/118012/overview" data-event="editorInfo-a-andreaDegasperi" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Andrea  Degasperi</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Early Cancer Institute, Department of Oncology, University of Cambridge, United Kingdom</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Materials and methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Data availability statement</a></li><li><a href="#h7">Ethics statement</a></li><li><a href="#h8">Author contributions</a></li><li><a href="#h9">Funding</a></li><li><a href="#h10">Acknowledgments</a></li><li><a href="#h11">Conflict of interest</a></li><li><a href="#h12">Publisher&#x2019;s note</a></li><li><a href="#h13">Supplementary material</a></li><li><a href="#h14">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1045817" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2023.1045817/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":947,"mainHeader":951},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":754,"currentArticlePageMetaInfo":755,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":28,"articleType":543,"stage":546,"keywords":548,"authors":554,"editors":684,"reviewers":693,"journal":712,"section":720,"impactMetrics":722,"volume":725,"articleVolume":726,"relatedArticles":727,"isPublishedV2":367,"contents":728,"files":731},1045817,"10.3389/fonc.2023.1045817","The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study",["Date","2023-01-20T13:01:54.000Z"],["Date","2022-09-16T02:58:38.000Z"],["Date","2023-02-10T00:00:00.000Z"],["Date","2025-11-25T03:35:48.613Z"],"Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also of the ethical nature and issues related to variant interpretation. Nowadays, genetic cancer screening standards are different in every country and usually encompass only only individuals with a personal or family history of a relevant cancer. Here we performed a broad genetic screening for cancer-related rare germline variants on population data from the Thousand Polish Genomes database based on 1076 Polish unrelated individuals that underwent whole genome sequencing (WGS). We identified 19 551 rare variants in 806 genes related to the oncological diseases, among them 89% have been located in non-coding regions. The combined BRCA1/BRCA2 pathogenic/likely pathogenic according to ClinVar variants in the unselected population of 1076 Poles was 0.42%, corresponding to nine carriers. Altogether, on the population level, we found especially problematic the assessment of the pathogenicity of variants and the relation of ACMG guidelines to the population frequency. Some of the variants may be overinterpreted as disease-causing due to their rarity or lack of annotation in the databases. On the other hand, some relevant variants may have been overseen given that there is little pooled population whole genome data on oncology. Before population WGS screening will become a standard, further studies are needed to assess the frequency of the variants suspected to be pathogenic on the population level and with reporting of likely benign variants.",{"id":544,"name":545},24,"Original Research",{"id":547,"name":19},18,[549,550,551,552,553],"Genetics","cancer risk","Poland","population cancer screening","Cancer",[555,564,571,577,585,591,599,604,611,619,628,637,646,652,660,665,671,677],{"id":556,"firstName":557,"middleName":19,"lastName":558,"givenNames":559,"isCorresponding":13,"isProfilePublic":13,"userId":556,"email":560,"affiliations":561},1434780,"Magdalena","Mroczek","Magdalena ","m.mroczek888@gmail.com",[562],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw",{"id":388,"firstName":565,"middleName":19,"lastName":566,"givenNames":567,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":568},"Jakub","Liu","Jakub ",[569],{"organizationName":570,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Biostatistics Group, Wrocaw University of Environmental and Life Sciences",{"id":388,"firstName":572,"middleName":19,"lastName":573,"givenNames":574,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":575},"Mateusz","Sypniewski","Mateusz ",[576],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":578,"middleName":19,"lastName":579,"givenNames":580,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":581},"Tadeusz","Piekowski","Tadeusz ",[582,583],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":584,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Postgraduate Medical Education Center",{"id":388,"firstName":586,"middleName":19,"lastName":587,"givenNames":588,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":589},"Bartosz","Itrych","Bartosz ",[590],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":592,"middleName":19,"lastName":593,"givenNames":594,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":595},"Joanna","Stojak","Joanna ",[596,597],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":598,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science",{"id":600,"firstName":586,"middleName":19,"lastName":601,"givenNames":588,"isCorresponding":367,"isProfilePublic":13,"userId":600,"email":-1,"affiliations":602},2082501,"Pronobis-Szczylik",[603],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":605,"middleName":19,"lastName":606,"givenNames":607,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":608},"Maria","Stpie","Maria ",[609],{"organizationName":610,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Sports Medicine, Doctoral School, Medical University of Lublin",{"id":612,"firstName":613,"middleName":19,"lastName":614,"givenNames":615,"isCorresponding":367,"isProfilePublic":13,"userId":612,"email":-1,"affiliations":616},2059509,"Elbieta","Kaja","Elbieta ",[617],{"organizationName":618,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences",{"id":620,"firstName":621,"middleName":19,"lastName":622,"givenNames":623,"isCorresponding":367,"isProfilePublic":13,"userId":620,"email":-1,"affiliations":624},2056992,"Maciej","Dbrowski","Maciej ",[625],{"organizationName":626,"countryName":627,"cityName":19,"stateName":19,"zipCode":19},"MNM Bioscience Inc.","United States",{"id":629,"firstName":630,"middleName":19,"lastName":631,"givenNames":632,"isCorresponding":367,"isProfilePublic":13,"userId":629,"email":-1,"affiliations":633},1121187,"Tomasz","Suchocki","Tomasz ",[634,635],{"organizationName":570,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":636,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"National Research Institute of Animal Production",{"id":388,"firstName":638,"middleName":19,"lastName":639,"givenNames":640,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":641},"Marzena","Wojtaszewska","Marzena ",[642,644],{"organizationName":643,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszw",{"organizationName":645,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Haematology, Frederic Chopin Provincial Specialist Hospital",{"id":388,"firstName":647,"middleName":19,"lastName":648,"givenNames":649,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":650},"Pawe","Zawadzki","Pawe ",[651],{"organizationName":626,"countryName":627,"cityName":19,"stateName":19,"zipCode":19},{"id":653,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":367,"isProfilePublic":13,"userId":653,"email":-1,"affiliations":657},989745,"Anna","Mach","Anna ",[658],{"organizationName":659,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Department of Psychiatry, Medical University of Warsaw",{"id":661,"firstName":647,"middleName":19,"lastName":662,"givenNames":649,"isCorresponding":367,"isProfilePublic":13,"userId":661,"email":-1,"affiliations":663},1150796,"Sztromwasser",[664],{"organizationName":626,"countryName":627,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":666,"middleName":19,"lastName":667,"givenNames":668,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":669},"Zbigniew J.","Krl","Zbigniew J. ",[670],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":672,"firstName":592,"middleName":19,"lastName":673,"givenNames":594,"isCorresponding":367,"isProfilePublic":13,"userId":672,"email":-1,"affiliations":674},25754,"Szyda",[675,676],{"organizationName":570,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":636,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},{"id":678,"firstName":679,"middleName":19,"lastName":680,"givenNames":681,"isCorresponding":367,"isProfilePublic":13,"userId":678,"email":-1,"affiliations":682},803713,"Paula","Dobosz","Paula ",[683],{"organizationName":563,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},[685],{"id":686,"firstName":687,"middleName":19,"lastName":688,"givenNames":689,"isCorresponding":367,"isProfilePublic":13,"userId":686,"email":-1,"affiliations":690},563114,"Elzbieta","Pluciennik","Elzbieta ",[691],{"organizationName":692,"countryName":551,"cityName":19,"stateName":19,"zipCode":19},"Medical University of Lodz",[694,703],{"id":695,"firstName":696,"middleName":19,"lastName":697,"givenNames":698,"isCorresponding":367,"isProfilePublic":13,"userId":695,"email":-1,"affiliations":699},37853,"Radka","Kaneva","Radka ",[700],{"organizationName":701,"countryName":702,"cityName":19,"stateName":19,"zipCode":19},"Medical University Sofia","Bulgaria",{"id":704,"firstName":705,"middleName":19,"lastName":706,"givenNames":707,"isCorresponding":367,"isProfilePublic":13,"userId":704,"email":-1,"affiliations":708},118012,"Andrea","Degasperi","Andrea ",[709],{"organizationName":710,"countryName":711,"cityName":19,"stateName":19,"zipCode":19},"Early Cancer Institute, Department of Oncology, University of Cambridge","United Kingdom",{"id":115,"slug":117,"name":116,"shortName":713,"electronicISSN":714,"field":715,"specialtyId":28,"journalSectionPaths":718},"Front. Oncol.","2234-943X",{"id":716,"domainId":717},57,2,[719],{"section":720},{"id":132,"name":133,"slug":134,"specialtyId":721},129,{"views":723,"downloads":724,"citations":388},3546,831,13,"Volume 13 - 2023",[],{"titleHtml":537,"fullTextHtml":729,"menuHtml":730},"\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1434780\" class=\"user-id-1434780\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1434780/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Magdalena Mroczek*&#x;&#x;&#x;\">Magdalena Mroczek\u003C/a>\u003Csup>1*&#x2020;&#x2020;&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jakub Liu&#x;&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jakub Liu\u003Csup>2&#x2020;&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Mateusz Sypniewski&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Mateusz Sypniewski\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Tadeusz Pie&#x;kowski,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Tadeusz Pie&#x144;kowski\u003Csup>1,3&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Bartosz Itrych&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Bartosz Itrych\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Joanna Stojak,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Joanna Stojak\u003Csup>1,4&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2082501\" class=\"user-id-2082501\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2082501/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Bartosz Pronobis-Szczylik&#x;\">Bartosz Pronobis-Szczylik\u003C/a>\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Maria St&#x;pie&#x;&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Maria St&#x119;pie&#x144;\u003Csup>5&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2059509\" class=\"user-id-2059509\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2059509/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"El&#xc;bieta Kaja&#x;\">El&#x17c;bieta Kaja\u003C/a>\u003Csup>6&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2056992\" class=\"user-id-2056992\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2056992/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Maciej D&#x;browski&#x;\">Maciej D&#x105;browski\u003C/a>\u003Csup>7&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1121187\" class=\"user-id-1121187\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1121187/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Tomasz Suchocki,&#x;\">Tomasz Suchocki\u003C/a>\u003Csup>2,8&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Marzena Wojtaszewska,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Marzena Wojtaszewska\u003Csup>9,10&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Pawe&#x; Zawadzki&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Pawe&#x142; Zawadzki\u003Csup>7&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/989745\" class=\"user-id-989745\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/989745/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Anna Mach&#x;\">Anna Mach\u003C/a>\u003Csup>11&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1150796\" class=\"user-id-1150796\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1150796/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Pawe&#x; Sztromwasser&#x;\">Pawe&#x142; Sztromwasser\u003C/a>\u003Csup>7&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zbigniew J. Kr&#xf;l&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zbigniew J. Kr&#xf3;l\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/25754\" class=\"user-id-25754\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/25754/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Joanna Szyda,&#x;\">Joanna Szyda\u003C/a>\u003Csup>2,8&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/803713\" class=\"user-id-803713\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/803713/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Paula Dobosz&#x;\">Paula Dobosz\u003C/a>\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Warsaw, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Biostatistics Group, Wroc&#x142;aw University of Environmental and Life Sciences, Wroc&#x142;aw, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Postgraduate Medical Education Center, Warsaw, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science, Jastrz&#x119;biec, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Department of Sports Medicine, Doctoral School, Medical University of Lublin, Lublin, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poznan, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>7\u003C/sup>\u003C/span>MNM Bioscience Inc., Cambridge, MA, United States\u003C/li>\u003Cli>\u003Cspan>\u003Csup>8\u003C/sup>\u003C/span>National Research Institute of Animal Production, Balice, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>9\u003C/sup>\u003C/span>Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzesz&#xf3;w, Rzesz&#xf3;w, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>10\u003C/sup>\u003C/span>Department of Haematology, Frederic Chopin Provincial Specialist Hospital, Rzesz&#xf3;w, Poland\u003C/li>\u003Cli>\u003Cspan>\u003Csup>11\u003C/sup>\u003C/span>Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland\u003C/li>\u003C/ul>\u003Cp>\u003Cstrong>Introduction:\u003C/strong> Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also regarding the ethical nature and issues related to variant interpretation. Nowadays, genetic cancer screening standards are different in every country and usually encompass only individuals with a personal or family history of relevant cancer.\u003C/p>\u003Cp>\u003Cstrong>Methods:\u003C/strong> Here we performed a broad genetic screening for cancer-related rare germline variants on population data from the Thousand Polish Genomes database based on 1076 Polish unrelated individuals that underwent whole genome sequencing (WGS). \u003C/p>\u003Cp>\u003Cstrong>Results:\u003C/strong> We identified 19 551 rare variants in 806 genes related to oncological diseases, among them 89% have been located in non-coding regions. The combined BRCA1/BRCA2 pathogenic/likely pathogenic according to ClinVar allele frequency in the unselected population of 1076 Poles was 0.42%, corresponding to nine carriers.\u003C/p>\u003Cp>\u003Cstrong>Discussion:\u003C/strong> Altogether, on the population level, we found especially problematic the assessment of the pathogenicity of variants and the relation of ACMG guidelines to the population frequency. Some of the variants may be overinterpreted as disease-causing due to their rarity or lack of annotation in the databases. On the other hand, some relevant variants may have been overseen given that there is little pooled population whole genome data on oncology. Before population WGS screening will become a standard, further studies are needed to assess the frequency of the variants suspected to be pathogenic on the population level and with reporting of likely benign variants.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\u003Cp class=\"mb15\">It has been over 20 years since the very first version of the entire human genome was released. Not a long time afterward, the scientific community agreed that cancer is a disease of the genome. Today, although advanced sequencing methods are available at a reasonable price and the role of significant genetic variants localized along the whole genome is quite well defined, the clinical implementation of whole-genome sequencing (WGS) in diagnosis and treatment remains in its infancy. Tumor sequencing (somatic variants) can provide valuable information regarding treatment response and outcomes, however, cannot explain all cancer cases. Around 5-14% of all cancers are caused by germline (inherited) variants (\u003Ca href=\"#B1\">1\u003C/a>). Usually, screening for germline variants related to oncological diseases encompasses only individuals with a personal or family history of relevant cancer. Here, we present the first whole-genome sequencing-based cancer population screening in the 1076 individuals from the Polish population.\u003C/p>\u003Cp class=\"mb15\">Cancer remains one of the major epidemiological challenges in Poland as the number of cancer deaths is increasing. In the last 50 years, it has risen by 2.5 times, and the survival rate is one of the lowest in Europe (\u003Ca href=\"#B2\">2\u003C/a>). In Poland, women are affected most often by breast (22.9%), lung (9.9%), corpus uteri (7.0%), colon (5.9%), and ovary (4.3%) cancers (\u003Ca href=\"#B2\">2\u003C/a>). Among Polish men, the most common are prostate (20.6%), lung (16.1%), colon (6.8%), and urinary bladder (6.4%) cancers (\u003Ca href=\"#B2\">2\u003C/a>). The Polish population has an especially low cancer survival rate with over 10 percentage points lower than the 5-year survival rate of other European countries (\u003Ca href=\"#B3\">3\u003C/a>). The most significant reasons for this are a too-late diagnosis caused by the lack of screening programs and poor access to the healthcare system (\u003Ca href=\"#B4\">4\u003C/a>). Other characteristics of the Polish cancer-related genetic landscape are relative homogeneity and a strong influence of the founder effects (\u003Ca href=\"#B5\">5\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">The benefits of screening and preventive treatments for individuals with pathogenic cancer-related variants in different populations depend on the prevalence and penetrance of the mutation, the mortality associated with the disease, the age of the person screened, the potential effects of preventive measures on the risk of developing the disease, quality of life, and costs (\u003Ca href=\"#B6\">6\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Some rare genetic variants have already been included in the populational screening, especially in isolated populations. Breast cancer prevention is one of the most broadly applied examples of population screening. The current screening strategy encompasses individuals with a personal or family history of relevant cancer and the criteria and screening for founder mutations in isolated populations, such as Ashkenazi Jews. In the Ashkenazi population, 3% of women carry one of the three ancient mutations: \u003Ci>BRCA1\u003C/i> 185delAG (c.68_69delAG), \u003Ci>BRCA1\u003C/i> 5382insC (c.5266dupC), or \u003Ci>BRCA2\u003C/i> 6174delT (c.5946delT) (\u003Ca href=\"#B7\">7\u003C/a>, \u003Ca href=\"#B8\">8\u003C/a>). In Poland breast cancer mutations \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> show a strong founder effect. The incidence of the founder breast cancer mutations in the unselected early-onset breast Polish population is around 6% (\u003Ca href=\"#B8\">8\u003C/a>). Around 80%-90% of the \u003Ci>BRCA1\u003C/i> mutations in Polish cancer families can be explained by one of three founder mutations (5382insC, C61G and 4153delA) (\u003Ca href=\"#B6\">6\u003C/a>). Although the identification of carriers of hereditary breast and ovarian cancer gene variants through family cancer history alone is suboptimal, population screening is still controversial. In one of the few population screening studies, it was shown that as many as 38 of 5908 women (0.64%) carried a clinically actionable pathogenic variant (\u003Ca href=\"#B9\">9\u003C/a>). 42% of pathogenic variant carriers did not have a first-degree relative with breast or ovarian cancer and the family history was very often not informative (\u003Ca href=\"#B9\">9\u003C/a>) Polish population has been examined mainly in the context of selected genes playing a role as a control for cancer patient studies. The population prevalence for combined founder \u003Ci>BRCA1\u003C/i> 5382insC and C61G variants in Poland was 0.25% (1/400) (\u003Ca href=\"#B10\">10\u003C/a>). The following prevalence for \u003Ci>BRCA1\u003C/i> variants has been found: 0.17% for c.5266dupC, 0.1% for c.3819del5, and 0.08% for C61G variant. The testing strategy is suboptimal and detects only a fraction of \u003Ci>BRCA\u003C/i> pathogenic/likely pathogenic (P/LP) variants carriers (\u003Ca href=\"#B11\">11\u003C/a>). In the Greater London Area, only 2.6% of total estimated carriers and 5.1% of detectable carriers have been identified in the general population with current NHS strategies (\u003Ca href=\"#B12\">12\u003C/a>). Given the rising number of risk management options and the availability of new sequencing technologies, a future screening strategy requires an urgent discussion.\u003C/p>\u003Cp class=\"mb0\">The aim of this study is to investigate germline cancer-related gene variants on the population level in Poland, to assess the type of variation (i.e., point or structural), to compare the frequencies with the frequency of corresponding variants estimated for the non-Finnish European population (NFE), and to interpret their relevance in the context of the family history-based testing. Our study is an extension of the study presented in Kaja et&#xa0;al. (\u003Ca href=\"#B13\">13\u003C/a>), however here we focus exclusively on the variants related to oncology, the frequency of these germline variants in a healthy genetically homogenous population and their potential significance on the clinical level. Further, we discuss the application of local genomic databases in oncology and the feasibility of populational cancer testing with WGS.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and methods\u003C/h2>\u003Ch3>The cohort\u003C/h3>\u003Cp class=\"mb15\">The cohort was described in detail in Kaja et&#xa0;al., 2022 (\u003Ca href=\"#B13\">13\u003C/a>). Briefly, the studied population was recruited through the project &#x201c;Search for genomic markers predicting the severity of the response to COVID- 19&#x201d; to the genetic predisposition to COVID-19 severity. Samples were collected from 1222 individuals of Polish origin (extended cohort), between April 2020 and April 2021. Among them 1076 were unrelated and did not suffer from any significant disease (core cohort), for a detailed cohort description see Kaja et&#xa0;al., 2022 (\u003Ca href=\"#B13\">13\u003C/a>). Samples encompassed the whole territory of Poland. All participants, guardians, or parents of the participants under 18 years of age, provided informed consent before the collection of blood samples and filling in the clinical data form, which included a questionnaire about the country of origin and chronic diseases. All participants signed informed consent. The ethical approval for the study was obtained from the Ethics Committee of the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw (decision nr: 41/2020 from 3 April 2020 and 125/2020 from 1 July 2020). The database containing anonymized genetic variants is available and can be downloaded as a VCF file from \u003Ca href=\"https://naszegenomy.pl/\">https://naszegenomy.pl/\u003C/a> after accepting the policy and filling in a short form.\u003C/p>\u003Cp class=\"mb0\">The core cohort consisted of 1076 unrelated individuals of Polish origin. The median age of participants was 45.4 (2&#x2013;99) years and there was a slight predominance of males (697 vs. 525). This is comparable to the median age in Poland. The core cohort characteristics are presented in \u003Ca href=\"#T1\">Table&#xa0;1\u003C/a>. The patients have initially been recruited for the COVID studies, independent of their chronic disease status. The analysis of clinical data demonstrated that the most common chronic self-reported diseases in the survey were: hypertension (13.0%), cancer (4.6%), diabetes (4.0%), and hypothyroidism or Hashimoto&#x2019;s disease (3.0%). For hypertension (13 vs. 60.28% (\u003Ca href=\"#B14\">14\u003C/a>)) and diabetes (4.0% vs. 6.97% (\u003Ca href=\"#B15\">15\u003C/a>)) the self-reported prevalence was lower than those reported in the studies, whereas for cancer mostly incidence data are available. The types of tumours identified in individuals from the extended cohort of 1222 people are reported in \u003Ca href=\"#h10\">Supplementary Table&#xa0;1\u003C/a>. Because access to the phenotypic information is restricted, we were not able to extract the cancer type and genetic variant information for the core cohort of 1076 only, due to technical reasons. The information on whether cancer has been confirmed pathologically was not collected. Also, the patient reported both benign and malignant tumours under the name &#x201c;cancer&#x201d;. No chronic disorders were reported by 86% of participants from the core cohort.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" name=\"table&#xa0;1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table&#xa0;1\u003C/strong> Sex and age characteristics of analyzed core cohort.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Whole-genome sequencing and data processing\u003C/h3>\u003Cp class=\"mb0\">DNA was isolated from the patient&#x2019;s peripheral blood. The library has been prepared using a TruSeq DNA PCR-free kit (Illumina Inc., San Diego, CA, USA) and 550 bp inserts. Sequencing was performed on the Illumina NovaSeq 6000 platform with the following parameters: 150 bp paired-end reads, an average read depth of 35.26&#xd7;. The quality has been assessed with FastQC v0.11.7 and mapped to the GRCh38 human reference genome. Single-nucleotide variants and short indels have been identified with DeepVariant v0.8.0 and genotyped all together with GL nexus v1.2.6-0-g4d057dc. Multiallelic variant calls were decomposed into monoallelic and normalized groups using BCFtools v1.9 (\u003Ca href=\"#B16\">16\u003C/a>). The variants have been annotated using the following resources: Ensembl Variant Effect Predictor v.107], including references to databases of genomic variants from ClinVar v. 20220624 and dbSNP build 151, variant population frequencies from the 1000 Genomes Project, and GnomAD v2.0.1 and v3.0, as well as pathogenicity scores, such as Polyphen-2, SIFT, DANN and CADD (\u003Ca href=\"#B13\">13\u003C/a>). All gene coordinates were padded with variants in the 10 kb range at both ends of the genes.\u003C/p>\u003Ch3>Cancer variant extraction and analysis\u003C/h3>\u003Cp class=\"mb15\">The variants associated with cancer were chosen based on the COSMIC database (Catalogue of Somatic Mutations in Cancer (\u003Ca href=\"#B17\">17\u003C/a>)) and literature review based on the PubMed search (\u003Ca href=\"#h10\">Supplementary Table&#xa0;2\u003C/a>). These variants were classified as having a high, moderate, or low impact based on Sequence Ontology terms. The annotation has been performed with a SNPEff software (for details see In-depth-NGS-Data-Analysis-Course). Furthermore, the variants were filtered to identify those with known pathogenicity in cancer, following the classification available in the ClinVar (version from 2022-06-24) database. The frequency of the variants in the Polish population (this study) was compared to the frequency estimated for the non-Finnish European (NFE EUR) population obtained from the gnomAD (accessed on 2022-07-02) database. NFE population is the most similar to the Polish population. The list of variants was filtered out for moderate and high impact as a first step, and then only variants annotated in gnomAD for the NFE were further considered. For better comparison, the differences in alternative allele frequencies (AF) between the Polish cohort and gnomAD NFE were expressed in terms of odds ratio defined as \u003Cmath xmlns=\"http://www.w3.org/1998/Math/MathML\" display=\"inline\" id=\"im1\">\u003Cmrow>\u003Cmfrac>\u003Cmrow>\u003Cmi mathsize=\"10.5pt\">A\u003C/mi>\u003Cmsub>\u003Cmi mathsize=\"10.5pt\">F\u003C/mi>\u003Cmrow>\u003Cmi mathsize=\"10.5pt\">P\u003C/mi>\u003Cmi mathsize=\"10.5pt\">L\u003C/mi>\u003C/mrow>\u003C/msub>\u003C/mrow>\u003Cmrow>\u003Cmi mathsize=\"10.5pt\">A\u003C/mi>\u003Cmsub>\u003Cmi mathsize=\"10.5pt\">F\u003C/mi>\u003Cmrow>\u003Cmi mathsize=\"10.5pt\">N\u003C/mi>\u003Cmi mathsize=\"10.5pt\">F\u003C/mi>\u003Cmi mathsize=\"10.5pt\">E\u003C/mi>\u003C/mrow>\u003C/msub>\u003C/mrow>\u003C/mfrac>\u003C/mrow>\u003C/math>where \u003Ci>AF\u003Csub>PL\u003C/sub>\u003C/i> is alternative allele frequency in polish cohort and \u003Ci>AF\u003Csub>NFE\u003C/sub>\u003C/i> is alternative allele frequency in gnomAD NFE. Statistical significance of odds ratios for each variant was estimated with Fisher&#x2019;s exact test and corrected for Bonferroni adjustments. The prevalence of carriers was counted as a ratio of positive samples to the total number of samples tested.\u003C/p>\u003Cp class=\"mb15\">To analyze genetic diversity AF from our database have been compared to exomes from gnomAD (gnomADe), genomes from gnomAD (gnomADg) and 1000 Genomes Project (1KGP) database (\u003Ca href=\"https://www.internationalgenome.org/\">https://www.internationalgenome.org/\u003C/a>, accessed on 2023-01-13). The African (AFR), Admixed American (AMR), East Asian (EAS), South Asian (SAS) and European, gnomADe and gnomADg NFE and EUR for 1KGP, ancestries were considered. Variants were filtered according to Combined Annotation-Dependent Depletion CADD (\u003Ca href=\"https://cadd.gs.washington.edu/,CADD&gt;=20\">https://cadd.gs.washington.edu/,CADD&gt;=20\u003C/a>), which is a deleteriousness measure.\u003C/p>\u003Cp class=\"mb0\">In the manuscript the conventional variant naming has been used. The HGVS nomenclature and genomic locations are available in the \u003Ca href=\"#h10\">Supplementary Table&#xa0;3\u003C/a>.\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3>The landscape of identified variants in the European context\u003C/h3>\u003Cp class=\"mb0\">Overall, 19551 variants related to oncological diseases have been identified in 806 different genes in the core cohort (\u003Ca href=\"#h10\">Supplementary Table&#xa0;2\u003C/a>). Among them, 316 variants were of high impact and 9835 variants were moderate impact variants. Importantly, in our study 9739 (75.87%) of the 12836 rare variants defined by MAF&lt; 0.01 were classified as singletons (\u003Ca href=\"#f1\">Figure&#xa0;1\u003C/a>). Among the variants, 1552 were located in introns and 17353 in exons. The MAF of variants of high, moderate and low impact (as assigned by VEP) was compared between NFE (gnomAD) and Polish populations (this study). The variant enrichment divided into medium and high frequency is presented in \u003Ca href=\"#f2\">Figure&#xa0;2\u003C/a>. High-impact variant for \u003Ci>FANCC\u003C/i> had a significant OR (p&lt;0.05) in the Polish population. Moderate impact variants with the highest OR (p&lt;0.05) in the Polish population were: \u003Ci>NUTM2B, MUC4, NOTCH1, NUTM2B, USP6\u003C/i> (\u003Ca href=\"#T2\">Table&#xa0;2\u003C/a>). Their functions and pathways they are involved in are presented in \u003Ca href=\"#T3\">Table&#xa0;3\u003C/a>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure&#xa0;1\u003C/strong> Distribution of alternative allele frequencies of indels and SNPs related to oncological diseases.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure&#xa0;2\u003C/strong> Distribution variants related to cancers in the PL population based on their impact.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" name=\"table&#xa0;2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table&#xa0;2\u003C/strong> High and moderate impact variants with a significantly higher frequency in the PL population as compared to the gnomAD in NFE population.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE&#xa0;3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" name=\"table&#xa0;3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table&#xa0;3\u003C/strong> Protein's function, pathways and types of cancers related to the high and moderate impact variants with the highest OR.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Polish population in the global context\u003C/h3>\u003Cp class=\"mb15\">To present variants related to oncology identified in our database in regard to global genetic diversity and other genetic and genomic databases, we compared the number of variants identified in the Polish population to different ancestries and from three databases. In the first step the analysis was performed for the \u003Ci>BRCA1/BRCA2\u003C/i> P/LP variants identified in the our database in the Polish population. In the context of 1KGP database, all these variants were unique across ancestries. The number of P/LP \u003Ci>BRCA1/BRCA2\u003C/i> variants shared according to gnomADg between Polish population (this study) and other ancestries presented as follows: NFE (n=5/7), AMR (n=3/7), AFR (n=2/7), EAS (n=1/7), SAS (n=1/7).\u003C/p>\u003Cp class=\"mb0\">In the second step, we analyzed the variants related to oncology in Poland in the broader perspective. Not to exclude common variants, but at the same time to use computational resources effectively, we analyzed the variants with CADD &gt; = 20 from the variants related o oncological diseases list. These included 8491 variants, among them 840 rare (MAF&lt;0.01) and 7651 common (MAF&gt;0.01). Among 8491 variants, 5647 were unique for Polish population (monomorphic) according to 1KGP database, 4392 according to gnomADe and 2315 according to gnomADg. The number of variants related to oncology shared between Polish cohort and particular ancestries is shown in \u003Ca href=\"#f3\">Figure&#xa0;3\u003C/a>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE&#xa0;3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure&#xa0;3\u003C/strong> Variants shared between Polish population (this study) and different ancestries according to 1KGP, gnomADe and gnomADg. Legend: AFR- African, AMR- Admixed American, EAS-East Asian, SAS-South Asian and EUR (European-EUR for 1KGP and NFE-European non-Finnish for gnomADe and gnomADg).\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Variants in BRCA1/BRCA2\u003C/h3>\u003Cp class=\"mb0\">In the Polish population, 45 different rare variants were identified within the \u003Ci>BRCA1\u003C/i> gene and 72 in the \u003Ci>BRCA2\u003C/i>. Among them in \u003Ci>BRCA1\u003C/i> two were of a high impact, 30 of a moderate impact and 13 of a low impact. Among \u003Ci>BRCA2\u003C/i> five were of high impact, 46 of moderate impact and 21 of low impact. According to ClinVar three variants in \u003Ci>BRCA1\u003C/i> were classified as P/LP (c.5266dupC, 3819del5, and c.181T&gt;G (p.Cys61Gly)) and four variants in \u003Ci>BRCA2\u003C/i> (c.658_659delGT, c.1813dupA, c.5238dup and c.9371A&gt;T) were classified as P/LP. The \u003Ci>BRCA1/BRCA2\u003C/i> variants and their AF are shown in \u003Ca href=\"#h10\">Supplementary Table&#xa0;4\u003C/a>. Altogether, the AF for the \u003Ci>BRCA1/BRCA2\u003C/i> P/LP variants according to ClinVar (\u003Ca href=\"#B18\">18\u003C/a>) in the unselected populations of 1076 patients in a genetically homogenous Polish population was 0.42%. That means that we identified 9 P/LP \u003Ci>BRCA1/BRCA2\u003C/i> variants in the unselected Polish population. AF for the three pathogenic \u003Ci>BRCA1\u003C/i> founder variants was 0.23%. None of the \u003Ci>BRCA1/BRCA2\u003C/i> variants reached a statistically relevant higher allele frequency in the Polish population comparing to other European populations, suggesting that this kind of studies require a much larger cohort.\u003C/p>\u003Ch3>Variants in non-BRCA1/BRCA2\u003C/h3>\u003Cp class=\"mb0\">Several genes in which the variants were identified, are related to hereditary cancer syndromes, such as \u003Ci>PALB2\u003C/i>, related to ovarian and breast cancer or \u003Ci>JAK2\u003C/i> (c.3323A&gt;G, p.Asn1108Ser) associated with lung adenocarcinoma, myeloproliferative neoplasm, breast invasive ductal carcinoma, polycythemia vera, and colon adenocarcinoma (\u003Ca href=\"#h10\">Supplementary Table&#xa0;5\u003C/a>). \u003Ci>RAD51\u003C/i> protein product is involved in DNA repair and is altered in 0.65% of all cancers with lung adenocarcinoma, glioblastoma and glioblastoma multiforme (\u003Ca href=\"#B19\">19\u003C/a>). Germline mutations in the \u003Ci>CDKN2A\u003C/i> strongly predispose to cutaneous melanoma (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B20\">20\u003C/a>). Although we identified a variant (c.194-3652G&gt;C) in the \u003Ci>CDKN2A\u003C/i> gene located only one bp distant from the pathogenic \u003Ci>CDKN2A\u003C/i> variant c.-34G&gt;T (\u003Ca href=\"#B21\">21\u003C/a>, \u003Ca href=\"#B22\">22\u003C/a>), after a thorough analysis the variant proved to be benign. Other variants reported as pathogenic/likely pathogenic/with conflicting interpretations of pathogenicity according to the ClinVar were located in the following genes: \u003Ci>MSH6\u003C/i> associated with Lynch Syndrome i.e. hereditary non-polyposis colorectal cancer (\u003Ca href=\"#B23\">23\u003C/a>), \u003Ci>PIK3CB\u003C/i>, which is altered in 1.62% of all cancers such as colon adenocarcinoma, prostate adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma; \u003Ci>RPN1\u003C/i> altered in 0.19% of all cancers with high grade ovarian serous adenocarcinoma, colon adenocarcinoma, oesophageal adenocarcinoma, bladder urothelial carcinoma (\u003Ca href=\"#B24\">24\u003C/a>). Although the variants in these genes have been described as enriched in cancer populations or considered pathogenic by expert panels, the evidence of variant pathogenicity is often reported in very small sample sizes comprising a few families in control and a diseased group and thus not being representative of the whole population.\u003C/p>\u003Ch3>Phenotype correlation\u003C/h3>\u003Cp class=\"mb0\">Variants in 5 genes (\u003Ci>RPN1, CDKN2A, HRAS, PALB2, CBFA2T3\u003C/i>) have been identified in 32 individuals with tumor from the extended cohort and classified as pathogenic, likely pathogenic, and VUS \u003Cstrong>(\u003C/strong>\u003Ca href=\"#h10\">Supplementary Table&#xa0;1\u003C/a>). Given the limited information on cancer in our study cohort, e.g., in 4 cases there is no information about the cancer type, it is difficult to correlate the cancer type with genetic variants. Variants in three genes (\u003Ci>RPN1, HRAS\u003C/i> and \u003Ci>PALB2\u003C/i>) were carried by several individuals with cancer in extended cohort. Ribophorin 1 (RPN1) is a major part of oligosaccharyltransferase complex, which takes part in the glycosylation process. \u003Ci>RPN1\u003C/i> is upregulated in breast cancer and has also been associated with several other cancers, such as high-grade ovarian serous adenocarcinoma, colon adenocarcinoma, oesophageal adenocarcinoma, and bladder urothelial carcinoma. As much as 7 out of 12 individuals from our cohort with cancer had a likely pathogenic variant on both alleles. Another recurrent variant was localized i\u003Ci>n HRAS\u003C/i> gene. HRAS is a known oncogene related to several different cancers, among them Costello syndrome, a rare condition predisposing to tumours in different parts of the body, epidermal tumours, head and neck cancer, bladder carcinoma, and with ovarian carcinoma patients, but was also identified in the healthy controls The variants frequency is not annotated in ClinVar so that it also requires further characterization on the populational level. The variant p.Ile1035Val in \u003Ci>PALB2\u003C/i>, associated with breast and ovarian cancers, was identified in two out of eight individuals with breast cancers and in one ovarian cancer person from the extended cohort. All these variants will be further followed up in the affected cohorts in Poland in further studies.\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">Oncology remains the major field that can benefit most from whole genome sequencing (\u003Ca href=\"#B25\">25\u003C/a>). The first collection of over 350 cancer-related genes has been created, protein-coding genes to be more specific, with new genes being added over time (\u003Ca href=\"#B26\">26\u003C/a>). More and more WGS is being performed in a variety of different populations, supporting the notion that WGS of different cohorts enhances the power to identify genetic associations (\u003Ca href=\"#B24\">24\u003C/a>, \u003Ca href=\"#B27\">27\u003C/a>&#x2013;\u003Ca href=\"#B30\">30\u003C/a>). Recently, in light of rising population consciousness in terms of cancer population testing and with sinking costs of genetic testing it has been suggested that genetic testing should be offered on the population level. Cancer-susceptibility-gene (CSG) testing might shift from bespoke tests towards whole genome or whole exome analysis as a part of comprehensive population-wide programmes; incorporating such strategy into healthcare systems, with equitable access for the entire population, will be challenging. These issues should especially be discussed, together with variant-of-unknown-significance (VUS) interpretation, penetrance, and genetic counseling. The&#xa0;Thousand Polish Genomes database can find several applications in oncology and show benefits in comparison to the other genomic databases in the following areas: analysis of the intron variants, calculating a polygenic risk score (PRS) and being a reference database for the Polish studies on cancer patients.\u003C/p>\u003Cp class=\"mb15\">Traditionally, most of the studies were focused on the identification of cancer mutations solely in protein-coding genes, ignoring the remaining 99% of the genome. Gene panels can detect only mutations in 0.01 &#x2013; 0.10% of the genome, at best. The main reason for it was that a large proportion of early NGS-based studies was constrained to whole exome sequencing -&#xa0;a more cost-effective way of ascertaining large samples, as well as the fact that the functional annotation of the non-protein coding part of the genome has constantly been updated and thus made more informative (\u003Ca href=\"#B31\">31\u003C/a>). In our study, 89% of the variants in cancer-related genes were identified in non-coding regions, although most of the database reported variants derived from the exons. Whole Genome Sequence (WGS) based analyses of thousands of genomes representing various cancer tissues revealed multiple cancer-driver events localised in non-coding regions of DNA such as promoters and introns, to name just a few. Such events include not only single nucleotide variations (SNV) but also small indels and larger structural changes (\u003Ca href=\"#B32\">32\u003C/a>). There are already some attempts to better understand the function of the non-coding regions. For example, on the large UK Biobank sample a depletion rank has been applied to characterize the function and importance of the non-coding variants. Surprisingly, among the 1% of regions with the lowest DR, 13.0% were coding and 87.0% were non-coding (\u003Ca href=\"#B33\">33\u003C/a>). This suggests the still not understood importance of non-coding regions.\u003C/p>\u003Cp class=\"mb15\">Rare variants in high/medium penetrance cancer-related genes, although significant, cannot explain the cancer genetic risk sufficiently. Some common variants (polymorphisms, SNPs with a frequency &gt;1%) may contribute to the individual high or moderate risks of developing cancer or alternatively may imply a lower risk of developing the malignant disease. Polygenic Risk Score (PRS) aggregates the effects of many genetic variants across the human genome into a single score, being an estimate of an individual&#x2019;s genetic liability to a trait or disease (\u003Ca href=\"#B34\">34\u003C/a>). PRS can be useful in the prediction of the progression and recurrence of cancer, which allows improving the efficiency of population-level screening. Recent studies showed that common variants may sufficiently assess personal risk, at least for some types of cancers, such as breast, colon, lungs, thyroid and prostate (\u003Ca href=\"#B35\">35\u003C/a>). For prostate cancer the combination of rare and common genetic variants has been reported to be the most efficient in the disease risk prediction (\u003Ca href=\"#B36\">36\u003C/a>). Black et&#xa0;al. (\u003Ca href=\"#B37\">37\u003C/a>) reported that a set of 72 SNPs PRS was predictive of prostate cancer and could be used to identify unaffected individuals at high risk of developing prostate cancer. In the case of breast cancer, Kapoor et&#xa0;al. (\u003Ca href=\"#B38\">38\u003C/a>) highlighted that the lifetime risk of breast cancer associated with classical risk factors was greater for women with higher PRS. The estimation of genome wide PRS for breast and prostate cancers showed that having a high PRS led from 21% to 38% higher lifetime risk, and 4 to 9 years earlier disease onset. PRSs improved model calculations over age, sex and clinical risk and substantiated the application of PRS in population screening (\u003Ca href=\"#B39\">39\u003C/a>). PRS may additionally play the role of biomarker or response markers for chemotherapy and be taken into consideration to reduce the costs of cancer screening (\u003Ca href=\"#B34\">34\u003C/a>). There are also critical voices on the use of PRS, especially in a clinical setting. Before being introduced to the clinics, PRS must provide significant discrimination and be applicable in terms of early detection and prevention. One of the concerns regarding PRS is the fact that most analyses performed, are based on European populations and may not be generalizable to other (e.g., Asian) populations (\u003Ca href=\"#B40\">40\u003C/a>). That is why understanding the cancer-related variants in the context of the country&#x2019;s population is crucial for the interpretation at the population level and later on in an individual context. Although the data gathered as part of this study do not include at the moment strictly cancer patients, they can, later on, serve as a population control for assessing PRS.\u003C/p>\u003Cp class=\"mb15\">To check the representation of the variants in genes related to oncology in the Polish cohorts, we compared them to the data of multiple ancestries from the global databases. For the \u003Ci>BRCA1/BRCA2\u003C/i> analysis, the pathogenic variants identified in this study for the Polish population were mostly shared with the NFE ancestry and just one common variant within the EAS and SAS ancestry was identified. As Polish \u003Ci>BRCA1/BRCA2\u003C/i> P/LP variants have a strong founder effect that is why as expected there are shared mainly with the European NFE population, which is the closest genetically. Most of these variants are not represented in the other ancestries. In the context of variants with a highest CADD (mostly common variants) located in the genes associated with cancer, when compared to the gomADg database, encompassing most of the variants, as many as 27% were monomorphic for Poles, but this was strongly dependent on the database. The result highlights the importance of creating a local database due to the fact that a large part of the variants related to oncological diseases is population specific and not shared not only between the various ancestries, but also between the same continent (PL vs. NFE). Moreover, the size of the database has a considerable meaning, while a low number of individuals can lead to bias. For example, 1KGP database encompasses around 3202 WGS individuals from different ancestries (\u003Ca href=\"#B41\">41\u003C/a>), while gnomAD has aggregated 15.708 genomes and 125.748 exomes (\u003Ca href=\"#B42\">42\u003C/a>). Although 1KGP database has several advantages, such as a broad representation of the human genetic variation among ancestries and inclusion of only healthy individuals, however considering only a small number of individuals may not properly illustrate the similarities and diversity between different ancestries in terms of germline variants related to cancer.\u003C/p>\u003Cp class=\"mb15\">The Thousand&#xa0;Polish Genomes database can be used as a reference database for germline cancer variants. To the best of our knowledge, this is the first study on the Polish population using a whole-genome sequencing approach for cancer predisposition screening. Previous studies focussed on selected genes and known founder mutation, although they have encompassed large cohorts, such as 16 229 healthy persons. The Thousand&#xa0;Polish Genomes database encompass also genetic modifiers and genetic biomarkers related to treatment outcomes. In Poland several projects targeted the discovery of new genes related to cancer and cancer susceptibility genes (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B44\">44\u003C/a>). The Thousand&#xa0;Polish Genomes database can provide population references for such studies. Also, recently it has been shown that it may be possible to construct germline variants from the discarded tumor sequencing reads (\u003Ca href=\"#B45\">45\u003C/a>). The local population can help to validate such a result. One of the most relevant issues is in assessing variant pathogenicity. This is a challenge also for the variants already reported in ClinVar. For example, the variant in \u003Ci>PALB2\u003C/i> (c.3103A&gt;G (p.Ile1035Val)) gene reported as having conflicting interpretations of pathogenicity in ClinVar and suggested of being pathogenic in the literature (\u003Ca href=\"#B46\">46\u003C/a>) was present in healthy individuals as well as in breast cancer individuals from the extended cohort Our study confirmed the presence of this \u003Ci>PALB2\u003C/i> (c.3103A&gt;G (p.Ile1035Val)) variant in the Polish core cohort in a very high AF (12.3%).\u003C/p>\u003Cp class=\"mb0\">Are we ready for population cancer screening using WGS? Given the sinking costs of sequencing technologies and the rising availability of prevention management alternatives, we are heading towards it. We identified nine P/LP variants in the \u003Ci>BRCA1/BRCA2\u003C/i> variants only in the unselected Polish population. However, especially on the individual level we are not able to interpret data reliably, for example in terms of PRS, and that is why we cannot make any prediction based on them. As a scientific and clinical community, we should further try to provide results of the negative association in databases like ClinVar, not only the positive ones. We should be aware of differences between populations, even within the same ethnicity group, and to be able to identify risk alleles we advocate for large cohorts. For now, cancer screening with WGS on a research basis in larger populations will show us how feasible the method could be in clinics.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Data availability statement\u003C/h2>\u003Cp class=\"mb0\">The datasets presented in this study can be found in online repositories. The names of the repository can be found below: \u003Ca href=\"https://1000polishgenomes.com\">https://1000polishgenomes.com\u003C/a>.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Ethics statement\u003C/h2>\u003Cp class=\"mb0\">The studies involving human participants were reviewed and approved by the Ethics Committee of the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw (decision nr: 41/2020 from 3 April 2020 and 125/2020 from 1 July 2020). The patients/participants provided their written informed consent to participate in this study.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Author contributions\u003C/h2>\u003Cp class=\"mb15\">Conceptualization, MM, PD, BI, JL. Formal analysis, MM, TS, JL. Data curation, TP, PD, PT, TS, JSt. Data generation, PD, PT, PZ, ZK, EK, MD, MW. Methodology, MM, MatS, TS, JSt, BP-S. Visualisation and writing&#x2014;original draft preparation, MM, JL, BI, JSz, BP-S, MarS. Writing&#x2014;reviewing and editing: JSz, PD, JSt, MD, BP-S, TP. Funding acquisition, ZK. Supervision: PD, JSz. All authors contributed to the article and approved the submitted version.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Funding\u003C/h2>\u003Cp class=\"mb15\">This research was partially funded by the The National Centre for Research and Development project SZPITALE-JEDNOIMIENNE/2/2020 &#x201c;Development of an innovative diagnostic test to assess the course of COVID-19 and post-death complications with the aid of whole genome analysis\".\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\u003Cp class=\"mb0\">We thank the patients for consenting to take part in this study.\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of interest\u003C/h2>\u003Cp class=\"mb15\">Author PS and MD are employed by MNM Bioscience. Author MatS, EK and PD were employed by MNM Bioscience.\u003C/p>\u003Cp class=\"mb0\">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Publisher&#x2019;s note\u003C/h2>\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Supplementary material\u003C/h2>\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2023.1045817/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2023.1045817/full#supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. \u003Ci>JAMA netw Open\u003C/i> (2022) 5(5):e2213070. doi: 10.1001/jamanetworkopen.2022.13070\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35594047/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jamanetworkopen.2022.13070\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TA+Yap&amp;author=A+Ashok&amp;author=J+Stoll&amp;author=E+Mauer&amp;author=VM+Nepomuceno&amp;author=KL+Blackwell&amp;publication_year=2022&amp;title=Prevalence%20of%20germline%20findings%20among%20tumors%20from%20cancer%20types%20lacking%20hereditary%20testing%20guidelines&amp;journal=JAMA+netw+Open&amp;volume=5&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Didkowska J, Wojciechowska U, Michalek IM, Caetano dos Santos FL. Cancer incidence and mortality in Poland in 2019. \u003Ci>Sci Rep\u003C/i> (2022) 12(1):10875.3. doi: 10.1038/s41598-022-14779-6\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41598-022-14779-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Didkowska&amp;author=U+Wojciechowska&amp;author=IM+Michalek&amp;author=FL+Caetano%20dos%20Santos&amp;publication_year=2022&amp;title=Cancer%20incidence%20and%20mortality%20in%20Poland%20in%202019&amp;journal=Sci+Rep&amp;volume=12&amp;pages=10875.3\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Burzy&#x144;ska M, Maniecka-Bry&#x142;a I, Pikala M. Trends of mortality due to breast cancer in Poland, 2000&#x2013;2016. \u003Ci>BMC Public Health\u003C/i> (2020) 20(1):120. doi: 10.1186/s12889-020-8256-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31996185/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12889-020-8256-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Burzy%C5%84ska&amp;author=I+Maniecka-Bry%C5%82a&amp;author=M+Pikala&amp;publication_year=2020&amp;title=Trends%20of%20mortality%20due%20to%20breast%20cancer%20in%20Poland%2C%202000%E2%80%932016&amp;journal=BMC+Public+Health&amp;volume=20&amp;pages=120\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. de Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999&#x2013;2007 by country and age: results of EUROCARE-5&#x2013;a population-based study. \u003Ci>Lancet Oncol\u003C/i> (2014) 15(1):23&#x2013;34. doi: 10.1016/S1470-2045(13)70546-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24314615/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1470-2045(13)70546-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+de%20Angelis&amp;author=M+Sant&amp;author=MP+Coleman&amp;author=S+Francisci&amp;author=P+Baili&amp;author=D+Pierannunzio&amp;publication_year=2014&amp;title=Cancer%20survival%20in%20Europe%201999%E2%80%932007%20by%20country%20and%20age%3A%20results%20of%20EUROCARE-5%E2%80%93a%20population-based%20study&amp;journal=Lancet+Oncol&amp;volume=15&amp;pages=23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. G&#xf3;rski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in polish families with breast-ovarian cancer. \u003Ci>Am J Hum Genet\u003C/i> (2000) 66(6):1963&#x2013;8. doi: 10.1086/302922\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10788334/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/302922\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B+G%C3%B3rski&amp;author=T+Byrski&amp;author=T+Huzarski&amp;author=A+Jakubowska&amp;author=J+Menkiszak&amp;author=J+Gronwald&amp;publication_year=2000&amp;title=Founder%20mutations%20in%20the%20BRCA1%20gene%20in%20polish%20families%20with%20breast-ovarian%20cancer&amp;journal=Am+J+Hum+Genet&amp;volume=66&amp;pages=1963-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. G&#xf3;rski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder \u003Ci>BRCA1\u003C/i> mutations in polish breast cancer families. \u003Ci>Int J Cancer\u003C/i> (2004) 110(5):683&#x2013;6. doi: 10.1002/ijc.20162\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15146557/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.20162\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B+G%C3%B3rski&amp;author=A+Jakubowska&amp;author=T+Huzarski&amp;author=T+Byrski&amp;author=J+Gronwald&amp;author=E+Grzybowska&amp;publication_year=2004&amp;title=A%20high%20proportion%20of%20founder%20BRCA1%20mutations%20in%20polish%20breast%20cancer%20families&amp;journal=Int+J+Cancer&amp;volume=110&amp;pages=683-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> among ashkenazi jews. \u003Ci>New Engl J Med\u003C/i> (1997) 336(20):1401&#x2013;8. doi: 10.1056/NEJM199705153362001\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9145676/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJM199705153362001\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JP+Struewing&amp;author=P+Hartge&amp;author=S+Wacholder&amp;author=SM+Baker&amp;author=M+Berlin&amp;author=M+McAdams&amp;publication_year=1997&amp;title=The%20risk%20of%20cancer%20associated%20with%20specific%20mutations%20of%20BRCA1%20and%20BRCA2%20among%20ashkenazi%20jews&amp;journal=New+Engl+J+Med&amp;volume=336&amp;pages=1401-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Lubi&#x144;ski J, G&#xf3;rski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fern&#xe1;ndez P, et al. BRCA1-positive breast cancers in young women from Poland. \u003Ci>Breast Cancer Res Treat\u003C/i> (2006) 99(1):71&#x2013;6. doi: 10.1007/s10549-006-9182-3\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16541315/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-006-9182-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Lubi%C5%84ski&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=T+Byrski&amp;author=J+Gronwald&amp;author=P+Serrano-Fern%C3%A1ndez&amp;publication_year=2006&amp;title=BRCA1-positive%20breast%20cancers%20in%20young%20women%20from%20Poland&amp;journal=Breast+Cancer+Res+Treat&amp;volume=99&amp;pages=71-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. \u003Ci>Genet Med\u003C/i> (2019) 21(4):913&#x2013;22. doi: 10.1038/s41436-018-0277-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30254378/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41436-018-0277-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SM+Rowley&amp;author=L+Mascarenhas&amp;author=L+Devereux&amp;author=N+Li&amp;author=KC+Amarasinghe&amp;author=M+Zethoven&amp;publication_year=2019&amp;title=Population-based%20genetic%20testing%20of%20asymptomatic%20women%20for%20breast%20and%20ovarian%20cancer%20susceptibility&amp;journal=Genet+Med&amp;volume=21&amp;pages=913-22\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, et al. Prevalence of the most frequent BRCA1 mutations in polish population. \u003Ci>J Appl Genet\u003C/i> (2011) 52(3):325&#x2013;30. doi: 10.1007/s13353-011-0040-6\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21503673/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s13353-011-0040-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Brozek&amp;author=C+Cybulska&amp;author=M+Ratajska&amp;author=M+Piatkowska&amp;author=A+Kluska&amp;author=A+Balabas&amp;publication_year=2011&amp;title=Prevalence%20of%20the%20most%20frequent%20BRCA1%20mutations%20in%20polish%20population&amp;journal=J+Appl+Genet&amp;volume=52&amp;pages=325-30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. \u003Ci>Nat Rev Clin Oncol\u003C/i> (2016) 13(1):41&#x2013;54. doi: 10.1038/nrclinonc.2015.173\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26483301/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrclinonc.2015.173\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WD+Foulkes&amp;author=BM+Knoppers&amp;author=C+Turnbull&amp;publication_year=2016&amp;title=Population%20genetic%20testing%20for%20cancer%20susceptibility%3A%20founder%20mutations%20to%20genomes&amp;journal=Nat+Rev+Clin+Oncol&amp;volume=13&amp;pages=41\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, et al. Current detection rates and time-to-detection of all identifiable BRCA carriers in the greater London population. \u003Ci>J Med Genet\u003C/i> (2018) 55(8):538&#x2013;45. doi: 10.1136/jmedgenet-2017-105195\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29622727/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmedgenet-2017-105195\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Manchanda&amp;author=O+Blyuss&amp;author=F+Gaba&amp;author=VS+Gordeev&amp;author=C+Jacobs&amp;author=M+Burnell&amp;publication_year=2018&amp;title=Current%20detection%20rates%20and%20time-to-detection%20of%20all%20identifiable%20BRCA%20carriers%20in%20the%20greater%20London%20population&amp;journal=J+Med+Genet&amp;volume=55&amp;pages=538-45\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Kaja E, Lejman A, Sielski D, Sypniewski M, Gambin T, Dawidziuk M, et al. The thousand polish genomes&#x2013;a database of polish variant allele frequencies. \u003Ci>Int J Mol Sci\u003C/i> (2022) 23(9):4532. doi: 10.3390/ijms23094532\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35562925/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3390/ijms23094532\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Kaja&amp;author=A+Lejman&amp;author=D+Sielski&amp;author=M+Sypniewski&amp;author=T+Gambin&amp;author=M+Dawidziuk&amp;publication_year=2022&amp;title=The%20thousand%20polish%20genomes%E2%80%93a%20database%20of%20polish%20variant%20allele%20frequencies&amp;journal=Int+J+Mol+Sci&amp;volume=23&amp;pages=4532\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Szuba A, Martynowicz H, Zato&#x144;ska K, Ilow R, Regulska-Ilow B, R&#xf3;&#x17c;a&#x144;ska D, et al. Prevalence of hypertension in polish population of PURE Poland study. \u003Ci>J Health Inequal\u003C/i> (2016) 2:157&#x2013;62. doi: 10.5114/jhi.2016.65356\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.5114/jhi.2016.65356\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Szuba&amp;author=H+Martynowicz&amp;author=K+Zato%C5%84ska&amp;author=R+Ilow&amp;author=B+Regulska-Ilow&amp;author=D+R%C3%B3%C5%BCa%C5%84ska&amp;publication_year=2016&amp;title=Prevalence%20of%20hypertension%20in%20polish%20population%20of%20PURE%20Poland%20study&amp;journal=J+Health+Inequal&amp;volume=2&amp;pages=157-62\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Topor-Madry R, Wojtyniak B, Strojek K, Rutkowski D, Bogus&#x142;awski S, Ignaszewska-Wyrzykowska A, et al. Prevalence of diabetes in Poland: a combined analysis of national databases. \u003Ci>Diabetic Med\u003C/i> (2019) 36(10):1209&#x2013;16. doi: 10.1111/dme.13949\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30889281/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/dme.13949\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Topor-Madry&amp;author=B+Wojtyniak&amp;author=K+Strojek&amp;author=D+Rutkowski&amp;author=S+Bogus%C5%82awski&amp;author=A+Ignaszewska-Wyrzykowska&amp;publication_year=2019&amp;title=Prevalence%20of%20diabetes%20in%20Poland%3A%20a%20combined%20analysis%20of%20national%20databases&amp;journal=Diabetic+Med&amp;volume=36&amp;pages=1209-16\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, et al. Mutation of the CDKN2A 5&#x2019; UTR creates an aberrant initiation codon and predisposes to melanoma. \u003Ci>Nat Genet\u003C/i> (1999) 21(1):128&#x2013;32. doi: 10.1038/5082\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/9916806/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/5082\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Liu&amp;author=D+Dilworth&amp;author=L+Gao&amp;author=J+Monzon&amp;author=A+Summers&amp;author=N+Lassam&amp;publication_year=1999&amp;title=Mutation%20of%20the%20CDKN2A%205%E2%80%99%20UTR%20creates%20an%20aberrant%20initiation%20codon%20and%20predisposes%20to%20melanoma&amp;journal=Nat+Genet&amp;volume=21&amp;pages=128-32\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. COSMIC. The Catalogue Of Somatic Mutations In Cancer. \u003Ca href=\"https://cancer.sanger.ac.uk/cosmic\">https://cancer.sanger.ac.uk/cosmic\u003C/a> (accessed on 01.03.2022).\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?title=COSMIC.%20The%20Catalogue%20Of%20Somatic%20Mutations%20In%20Cancer&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Szwiec M, Jakubowska A, G&#xf3;rski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. \u003Ci>Clin Genet\u003C/i> (2015) 87(3):288&#x2013;92. doi: 10.1111/cge.12360\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24528374/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12360\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Szwiec&amp;author=A+Jakubowska&amp;author=B+G%C3%B3rski&amp;author=T+Huzarski&amp;author=J+Tomiczek-Szwiec&amp;author=J+Gronwald&amp;publication_year=2015&amp;title=Recurrent%20mutations%20of%20BRCA1%20and%20BRCA2%20in%20Poland%3A%20an%20update&amp;journal=Clin+Genet&amp;volume=87&amp;pages=288-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Andr&#xe9; F, Arnedos M, Baras AS, Baselga J, Bedard PL, Berger MF, et al. AACR project GENIE: Powering precision medicine through an international consortium. \u003Ci>Cancer Discovery\u003C/i> (2017) 7(8):818&#x2013;31. doi: 10.1158/2159-8290.CD-17-0151\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28572459/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/2159-8290.CD-17-0151\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Andr%C3%A9&amp;author=M+Arnedos&amp;author=AS+Baras&amp;author=J+Baselga&amp;author=PL+Bedard&amp;author=MF+Berger&amp;publication_year=2017&amp;title=AACR%20project%20GENIE%3A%20Powering%20precision%20medicine%20through%20an%20international%20consortium&amp;journal=Cancer+Discovery&amp;volume=7&amp;pages=818-31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Harland M, Cust AE, Badenas C, Chang Y-M, Holland EA, Aguilera P, et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the united kingdom. \u003Ci>Hered Cancer Clin Pract\u003C/i> (2014) 12(1):20. doi: 10.1186/1897-4287-12-20\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25780468/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1897-4287-12-20\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Harland&amp;author=AE+Cust&amp;author=C+Badenas&amp;author=Y-M+Chang&amp;author=EA+Holland&amp;author=P+Aguilera&amp;publication_year=2014&amp;title=Prevalence%20and%20predictors%20of%20germline%20CDKN2A%20mutations%20for%20melanoma%20cases%20from%20Australia%2C%20Spain%20and%20the%20united%20kingdom&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=12&amp;pages=20\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. \u003Ci>J Invest Dermatol\u003C/i> (2006) 126(3):660&#x2013;6. doi: 10.1038/sj.jid.5700094\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16397522/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.jid.5700094\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MJ+Eliason&amp;author=AA+Larson&amp;author=SR+Florell&amp;author=JJ+Zone&amp;author=LA+Cannon-Albright&amp;author=WE+Samlowski&amp;publication_year=2006&amp;title=Population-based%20prevalence%20of%20CDKN2A%20mutations%20in%20Utah%20melanoma%20families&amp;journal=J+Invest+Dermatol&amp;volume=126&amp;pages=660-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Puig S, Potrony M, Cuellar F, Puig-Butille JA, Carrera C, Aguilera P, et al. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. \u003Ci>Genet Med\u003C/i> (2016) 18(7):727&#x2013;36. doi: 10.1038/gim.2015.160\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26681309/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2015.160\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Puig&amp;author=M+Potrony&amp;author=F+Cuellar&amp;author=JA+Puig-Butille&amp;author=C+Carrera&amp;author=P+Aguilera&amp;publication_year=2016&amp;title=Characterization%20of%20individuals%20at%20high%20risk%20of%20developing%20melanoma%20in%20Latin%20America%3A%20bases%20for%20genetic%20counseling%20in%20melanoma&amp;journal=Genet+Med&amp;volume=18&amp;pages=727-36\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Lee S-C, Guo J-Y, Lim R, Soo R, Koay E, Salto-Tellez M, et al. Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in southeast Asia. \u003Ci>Clin Genet\u003C/i> (2005) 68(2):137&#x2013;45. doi: 10.1111/j.1399-0004.2005.00469.x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15996210/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1399-0004.2005.00469.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S-C+Lee&amp;author=J-Y+Guo&amp;author=R+Lim&amp;author=R+Soo&amp;author=E+Koay&amp;author=M+Salto-Tellez&amp;publication_year=2005&amp;title=Clinical%20and%20molecular%20characteristics%20of%20hereditary%20non-polyposis%20colorectal%20cancer%20families%20in%20southeast%20Asia&amp;journal=Clin+Genet&amp;volume=68&amp;pages=137-45\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Besenbacher S, Liu S, Izarzugaza JMG, Grove J, Belling K, Bork-Jensen J, et al. Novel variation and \u003Ci>de novo\u003C/i> mutation rates in population-wide \u003Ci>de novo\u003C/i> assembled Danish trios. \u003Ci>Nat Commun\u003C/i> (2015) 6(1):5969. doi: 10.1038/ncomms6969\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25597990/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ncomms6969\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Besenbacher&amp;author=S+Liu&amp;author=JMG+Izarzugaza&amp;author=J+Grove&amp;author=K+Belling&amp;author=J+Bork-Jensen&amp;publication_year=2015&amp;title=Novel%20variation%20and%20de%20novo%20mutation%20rates%20in%20population-wide%20de%20novo%20assembled%20Danish%20trios&amp;journal=Nat+Commun&amp;volume=6&amp;pages=5969\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. \u003Ci>Nature\u003C/i> (2009) 458(7239):719&#x2013;24. doi: 10.1038/nature07943\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19360079/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature07943\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MR+Stratton&amp;author=PJ+Campbell&amp;author=PA+Futreal&amp;publication_year=2009&amp;title=The%20cancer%20genome&amp;journal=Nature&amp;volume=458&amp;pages=719-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. \u003Ci>Nat Rev Cancer\u003C/i> (2004) 4(3):177&#x2013;83. doi: 10.1038/nrc1299\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14993899/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc1299\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PA+Futreal&amp;author=L+Coin&amp;author=M+Marshall&amp;author=T+Down&amp;author=T+Hubbard&amp;author=R+Wooster&amp;publication_year=2004&amp;title=A%20census%20of%20human%20cancer%20genes&amp;journal=Nat+Rev+Cancer&amp;volume=4&amp;pages=177-83\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Gilly A, Suveges D, Kuchenbaecker K, Pollard M, Southam L, Hatzikotoulas K, et al. Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits. \u003Ci>Nat Commun\u003C/i> (2018) 9(1):4674. doi: 10.1038/s41467-018-07070-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30405126/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41467-018-07070-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Gilly&amp;author=D+Suveges&amp;author=K+Kuchenbaecker&amp;author=M+Pollard&amp;author=L+Southam&amp;author=K+Hatzikotoulas&amp;publication_year=2018&amp;title=Cohort-wide%20deep%20whole%20genome%20sequencing%20and%20the%20allelic%20architecture%20of%20complex%20traits&amp;journal=Nat+Commun&amp;volume=9&amp;pages=4674\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Boomsma DI, Wijmenga C, Slagboom EP, Swertz MA, Karssen LC, Abdellaoui A, et al. The genome of the Netherlands: design, and project goals. \u003Ci>Eur J Hum Genet\u003C/i> (2014) 22(2):221&#x2013;7. doi: 10.1038/ejhg.2013.118\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23714750/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ejhg.2013.118\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DI+Boomsma&amp;author=C+Wijmenga&amp;author=EP+Slagboom&amp;author=MA+Swertz&amp;author=LC+Karssen&amp;author=A+Abdellaoui&amp;publication_year=2014&amp;title=The%20genome%20of%20the%20Netherlands%3A%20design%2C%20and%20project%20goals&amp;journal=Eur+J+Hum+Genet&amp;volume=22&amp;pages=221-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Telenti A, Pierce LCT, Biggs WH, di Iulio J, Wong EHM, Fabani MM, et al. Deep sequencing of 10,000 human genomes. \u003Ci>Proc Natl Acad Sci\u003C/i> (2016) 113(42):11901&#x2013;6. doi: 10.1073/pnas.1613365113\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27702888/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1073/pnas.1613365113\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Telenti&amp;author=LCT+Pierce&amp;author=WH+Biggs&amp;author=J+di%20Iulio&amp;author=EHM+Wong&amp;author=MM+Fabani&amp;publication_year=2016&amp;title=Deep%20sequencing%20of%2010%2C000%20human%20genomes&amp;journal=Proc+Natl+Acad+Sci&amp;volume=113&amp;pages=11901-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Gudbjartsson DF, Helgason H, Gudjonsson SA, Zink F, Oddson A, Gylfason A, et al. Large-Scale whole-genome sequencing of the icelandic population. \u003Ci>Nat Genet\u003C/i> (2015) 47(5):435&#x2013;44. doi: 10.1038/ng.3247\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25807286/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.3247\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DF+Gudbjartsson&amp;author=H+Helgason&amp;author=SA+Gudjonsson&amp;author=F+Zink&amp;author=A+Oddson&amp;author=A+Gylfason&amp;publication_year=2015&amp;title=Large-Scale%20whole-genome%20sequencing%20of%20the%20icelandic%20population&amp;journal=Nat+Genet&amp;volume=47&amp;pages=435-44\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Sun Y, Ruivenkamp CAL, Hoffer MJV, Vrijenhoek T, Kriek M, van Asperen CJ, et al. Next-generation diagnostics: Gene panel, exome, or whole genome? \u003Ci>Hum Mutat\u003C/i> (2015) 36(6):648&#x2013;55. doi: 10.1002/humu.22783\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25772376/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.22783\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Sun&amp;author=CAL+Ruivenkamp&amp;author=MJV+Hoffer&amp;author=T+Vrijenhoek&amp;author=M+Kriek&amp;author=CJ+van%20Asperen&amp;publication_year=2015&amp;title=Next-generation%20diagnostics%3A%20Gene%20panel%2C%20exome%2C%20or%20whole%20genome&amp;journal=Hum+Mutat&amp;volume=36&amp;pages=648-55\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. \u003Ci>Nat Rev Cancer\u003C/i> (2018) 18(1):5&#x2013;18. doi: 10.1038/nrc.2017.99\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29170536/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc.2017.99\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Anastasiadou&amp;author=LS+Jacob&amp;author=FJ+Slack&amp;publication_year=2018&amp;title=Non-coding%20RNA%20networks%20in%20cancer&amp;journal=Nat+Rev+Cancer&amp;volume=18&amp;pages=5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> 33. Halldorsson B, Eggertsson HP, Moore KHS, Hauswedell H, Eiriksson O, Ulfarsson MO, et al. The sequences of 150,119 genomes in the UK biobank. \u003Ci>Nature\u003C/i> (2022) 607(7920):732&#x2013;40. doi: 10.1038/s41586-022-04965-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/35859178/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41586-022-04965-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B+Halldorsson&amp;author=HP+Eggertsson&amp;author=KHS+Moore&amp;author=H+Hauswedell&amp;author=O+Eiriksson&amp;author=MO+Ulfarsson&amp;publication_year=2022&amp;title=The%20sequences%20of%20150%2C119%20genomes%20in%20the%20UK%20biobank&amp;journal=Nature&amp;volume=607&amp;pages=732-40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> 34. Sud A, Turnbull C, Houlston R. Will polygenic risk scores for cancer ever be clinically useful? \u003Ci>NPJ Precis Onc\u003C/i> (2021) 5:40. doi: 10.1038/s41698-021-00176-1\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/s41698-021-00176-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Sud&amp;author=C+Turnbull&amp;author=R+Houlston&amp;publication_year=2021&amp;title=Will%20polygenic%20risk%20scores%20for%20cancer%20ever%20be%20clinically%20useful&amp;journal=NPJ+Precis+Onc&amp;volume=5&amp;pages=40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> 35. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. \u003Ci>Hum Mol Genet\u003C/i> (2019) 28(R2):R133&#x2013;42. doi: 10.1093/hmg/ddz187\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31363735/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/ddz187\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SA+Lambert&amp;author=G+Abraham&amp;author=M+Inouye&amp;publication_year=2019&amp;title=Towards%20clinical%20utility%20of%20polygenic%20risk%20scores&amp;journal=Hum+Mol+Genet&amp;volume=28&amp;pages=R133-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> 36. Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk. \u003Ci>Eur Urol\u003C/i> (2021) 80(2):134&#x2013;8. doi: 10.1016/j.eururo.2021.04.013\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33941403/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.eururo.2021.04.013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BF+Darst&amp;author=X+Sheng&amp;author=RA+Eeles&amp;author=Z+Kote-Jarai&amp;author=DV+Conti&amp;author=CA+Haiman&amp;publication_year=2021&amp;title=Combined%20effect%20of%20a%20polygenic%20risk%20score%20and%20rare%20genetic%20variants%20on%20prostate%20cancer%20risk&amp;journal=Eur+Urol&amp;volume=80&amp;pages=134-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> 37. Black MH, Li S, LaDuca H, Lo MT, Chen J, Hoiness R, et al. Validation of a prostate cancer polygenic risk score. \u003Ci>Prostate\u003C/i> (2020) 80(15):1314&#x2013;21. doi: 10.1002/pros.24058\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33258481/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/pros.24058\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MH+Black&amp;author=S+Li&amp;author=H+LaDuca&amp;author=MT+Lo&amp;author=J+Chen&amp;author=R+Hoiness&amp;publication_year=2020&amp;title=Validation%20of%20a%20prostate%20cancer%20polygenic%20risk%20score&amp;journal=Prostate&amp;volume=80&amp;pages=1314-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> 38. Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindstr&#xf6;m S, Behrens S, et al. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. \u003Ci>J Natl Cancer Inst\u003C/i> (2021) 113(3):329&#x2013;37. doi: 10.1093/jnci/djaa056\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32359158/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/jnci/djaa056\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=PM+Kapoor&amp;author=N+Mavaddat&amp;author=PP+Choudhury&amp;author=AN+Wilcox&amp;author=S+Lindstr%C3%B6m&amp;author=S+Behrens&amp;publication_year=2021&amp;title=Combined%20associations%20of%20a%20polygenic%20risk%20score%20and%20classical%20risk%20factors%20with%20breast%20cancer%20risk&amp;journal=J+Natl+Cancer+Inst&amp;volume=113&amp;pages=329-37\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> 39. Mars N, Koskela JT, Ripatti P, Kiiskinen T, Havulinna AS, Lindbohm JV, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. \u003Ci>Nat Med\u003C/i> (2020) 26(4):549&#x2013;57. doi: 10.1038/s41591-020-0800-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32273609/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41591-020-0800-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Mars&amp;author=JT+Koskela&amp;author=P+Ripatti&amp;author=T+Kiiskinen&amp;author=AS+Havulinna&amp;author=JV+Lindbohm&amp;publication_year=2020&amp;title=Polygenic%20and%20clinical%20risk%20scores%20and%20their%20impact%20on%20age%20at%20onset%20and%20prediction%20of%20cardiometabolic%20diseases%20and%20common%20cancers&amp;journal=Nat+Med&amp;volume=26&amp;pages=549-57\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> 40. Cavazos TB, Witte JS. Inclusion of variants discovered from diverse populations improves polygenic risk score transferability. \u003Ci>HGG Adv\u003C/i> (2021) 2(1):100017. doi: 10.1016/j.xhgg.2020.100017\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33564748/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.xhgg.2020.100017\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TB+Cavazos&amp;author=JS+Witte&amp;publication_year=2021&amp;title=Inclusion%20of%20variants%20discovered%20from%20diverse%20populations%20improves%20polygenic%20risk%20score%20transferability&amp;journal=HGG+Adv&amp;volume=2&amp;pages=100017\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> 41. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-coverage whole-genome sequencing of the expanded 1000 genomes project cohort including 602 trios. \u003Ci>Cell\u003C/i> (2022) 185(18):3426&#x2013;3440.e19. doi: 10.1016/j.cell.2022.08.004\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/36055201/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cell.2022.08.004\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Byrska-Bishop&amp;author=US+Evani&amp;author=X+Zhao&amp;author=AO+Basile&amp;author=HJ+Abel&amp;author=AA+Regier&amp;publication_year=2022&amp;title=High-coverage%20whole-genome%20sequencing%20of%20the%20expanded%201000%20genomes%20project%20cohort%20including%20602%20trios&amp;journal=Cell&amp;volume=185&amp;pages=3426\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> 42. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. \u003Ci>Nature\u003C/i> (2020) 581(7809):434&#x2013;43. doi: 10.1038/s41586-020-2308-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32461654/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41586-020-2308-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KJ+Karczewski&amp;author=LC+Francioli&amp;author=G+Tiao&amp;author=BB+Cummings&amp;author=J+Alf%C3%B6ldi&amp;author=Q+Wang&amp;publication_year=2020&amp;title=The%20mutational%20constraint%20spectrum%20quantified%20from%20variation%20in%20141%2C456%20humans&amp;journal=Nature&amp;volume=581&amp;pages=434-43\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> 43. Cybulski C, Carrot-Zhang J, Rivera B, Kashyap A, Woko&#x142;orczyk D, Giroux S, et al. Germline RECQL mutations are associated with breast cancer susceptibility. \u003Ci>Nat Genet\u003C/i> (2015) 47(6):643&#x2013;6. doi: 10.1038/ng.3284\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25915596/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ng.3284\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=J+Carrot-Zhang&amp;author=B+Rivera&amp;author=A+Kashyap&amp;author=D+Woko%C5%82orczyk&amp;author=S+Giroux&amp;publication_year=2015&amp;title=Germline%20RECQL%20mutations%20are%20associated%20with%20breast%20cancer%20susceptibility&amp;journal=Nat+Genet&amp;volume=47&amp;pages=643-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> 44. Cybulski C, G&#xf3;rski B, Debniak T, Gliniewicz B, Mierzejewski M, Masoj&#x107; B, et al. NBS1 is a prostate cancer susceptibility gene. \u003Ci>Cancer Res\u003C/i> (2004) 64(4):1215&#x2013;9. doi: 10.1158/0008-5472.CAN-03-2502\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/14973119/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/0008-5472.CAN-03-2502\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Cybulski&amp;author=B+G%C3%B3rski&amp;author=T+Debniak&amp;author=B+Gliniewicz&amp;author=M+Mierzejewski&amp;author=B+Masoj%C4%87&amp;publication_year=2004&amp;title=NBS1%20is%20a%20prostate%20cancer%20susceptibility%20gene&amp;journal=Cancer+Res&amp;volume=64&amp;pages=1215-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> 45. Gusev A, Groha S, Taraszka K, Semenov YR, Zaitlen N. Constructing germline research cohorts from the discarded reads of clinical tumor sequences. \u003Ci>Genome Med\u003C/i> (2021) 13(1):179. doi: 10.1186/s13073-021-00999-4\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34749793/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13073-021-00999-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Gusev&amp;author=S+Groha&amp;author=K+Taraszka&amp;author=YR+Semenov&amp;author=N+Zaitlen&amp;publication_year=2021&amp;title=Constructing%20germline%20research%20cohorts%20from%20the%20discarded%20reads%20of%20clinical%20tumor%20sequences&amp;journal=Genome+Med&amp;volume=13&amp;pages=179\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> 46. Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman A-R, et al. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. \u003Ci>Modern Pathol\u003C/i> (2016) 29(11):1381&#x2013;9. doi: 10.1038/modpathol.2016.135\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1038/modpathol.2016.135\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KL+Ring&amp;author=AS+Bruegl&amp;author=BA+Allen&amp;author=EP+Elkin&amp;author=N+Singh&amp;author=A-R+Hartman&amp;publication_year=2016&amp;title=Germline%20multi-gene%20hereditary%20cancer%20panel%20testing%20in%20an%20unselected%20endometrial%20cancer%20cohort&amp;journal=Modern+Pathol&amp;volume=29&amp;pages=1381-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> genetics, cancer risk, Poland, population cancer screening, cancer\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Mroczek M, Liu J, Sypniewski M, Pie&#x144;kowski T, Itrych B, Stojak J, Pronobis-Szczylik B, St&#x119;pie&#x144; M, Kaja E, D&#x105;browski M, Suchocki T, Wojtaszewska M, Zawadzki P, Mach A, Sztromwasser P, Kr&#xf3;l ZJ, Szyda J and Dobosz P (2023) The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study. \u003Ci>Front. Oncol.\u003C/i> 13:1045817. doi: 10.3389/fonc.2023.1045817\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 16 September 2022; \u003Cspan>Accepted:\u003C/span> 20 January 2023;\u003Cbr>\u003Cspan>Published:\u003C/span> 10 February 2023.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/563114\">Elzbieta Pluciennik\u003C/a>, Medical University of Lodz, Poland\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/37853\">Radka Kaneva\u003C/a>, Medical University Sofia, Bulgaria\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/118012\">Andrea Degasperi\u003C/a>, University of Cambridge, United Kingdom\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#xa9; 2023 Mroczek, Liu, Sypniewski, Pie&#x144;kowski, Itrych, Stojak, Pronobis-Szczylik, St&#x119;pie&#x144;, Kaja, D&#x105;browski, Suchocki, Wojtaszewska, Zawadzki, Mach, Sztromwasser, Kr&#xf3;l, Szyda and Dobosz. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Magdalena Mroczek, \u003Ca id=\"encmail\">bS5tcm9jemVrODg4QGdtYWlsLmNvbQ==\u003C/a>\u003C/p>\u003Cp>\u003Cspan>\u003Csup>&#x2020;\u003C/sup>\u003C/span>These authors have contributed equally to this work and share first authorship\u003C/p>\u003Cp>\u003Cspan>\u003Csup>&#x2021;\u003C/sup>ORCID\u003C/span>: Magdalena Mroczek, \u003Ca href=\"https://orcid.org/0000-0002-8731-0540\">orcid.org/0000-0002-8731-0540\u003C/a>\u003Cbr>Jakub Liu, \u003Ca href=\"https://orcid.org/0000-0003-4788-8417\">orcid.org/0000-0003-4788-8417\u003C/a>\u003Cbr>Mateusz Sypniewski, \u003Ca href=\"https://orcid.org/0000-0002-0108-0255\">orcid.org/0000-0002-0108-0255\u003C/a>\u003Cbr>Tadeusz Pie&#x144;kowski, \u003Ca href=\"https://orcid.org/0000-0002-0110-5950\">orcid.org/0000-0002-0110-5950\u003C/a>\u003Cbr>Bartosz Itrych, \u003Ca href=\"https://orcid.org/0000-0002-2608-1289\">orcid.org/0000-0002-2608-1289\u003C/a>\u003Cbr>Joanna Stojak, \u003Ca href=\"https://orcid.org/0000-0003-2423-5026\">orcid.org/0000-0003-2423-5026\u003C/a>\u003Cbr>Bartosz Pronobis-Szczylik, \u003Ca href=\"https://orcid.org/0000-0001-5220-9859\">orcid.org/0000-0001-5220-9859\u003C/a>\u003Cbr>Maria St&#x119;pie&#x144;, \u003Ca href=\"https://orcid.org/0000-0002-3377-4665\">orcid.org/0000-0002-3377-4665\u003C/a>\u003Cbr>El&#x17c;bieta Kaja, \u003Ca href=\"https://orcid.org/0000-0003-1277-6140\">orcid.org/0000-0003-1277-6140\u003C/a>\u003Cbr>Maciej D&#x105;browski, \u003Ca href=\"https://orcid.org/0000-0003-4150-3985\">orcid.org/0000-0003-4150-3985\u003C/a>\u003Cbr>Tomasz Suchocki, \u003Ca href=\"https://orcid.org/0000-0002-8530-3486\">orcid.org/0000-0002-8530-3486\u003C/a>\u003Cbr>Marzena Wojtaszewska, \u003Ca href=\"https://orcid.org/0000-0002-8979-2723\">orcid.org/0000-0002-8979-2723\u003C/a>\u003Cbr>Pawe&#x142; Zawadzki, \u003Ca href=\"https://orcid.org/0000-0002-9032-2315\">orcid.org/0000-0002-9032-2315\u003C/a>\u003Cbr>Anna Mach, \u003Ca href=\"https://orcid.org/0000-0002-2453-5320\">orcid.org/0000-0002-2453-5320\u003C/a>\u003Cbr>Pawe&#x142; Sztromwasser, \u003Ca href=\"https://orcid.org/0000-0002-0661-8800\">orcid.org/0000-0002-0661-8800\u003C/a>\u003Cbr>Zbigniew J. Kr&#xf3;l, \u003Ca href=\"https://orcid.org/0000-0003-3162-8813\">orcid.org/0000-0003-3162-8813\u003C/a>\u003Cbr>Joanna Szyda, \u003Ca href=\"https://orcid.org/0000-0001-9688-0193\">orcid.org/0000-0001-9688-0193\u003C/a>\u003Cbr>Paula Dobosz, \u003Ca href=\"https://orcid.org/0000-0002-5134-0975\">orcid.org/0000-0002-5134-0975\u003C/a>\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Materials and methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Data availability statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Ethics statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Author contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Funding\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Acknowledgments\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Conflict of interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h12\">Publisher&#x2019;s note\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">Supplementary material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h14\">References\u003C/a>\u003C/li>\u003C/ul>",[732,737,742,745,750],{"name":733,"fileServerPackageEntryId":19,"fileServerId":734,"fileServerVersionNumber":391,"type":735},"EPUB.epub","1045817/epub",{"code":736,"name":736},"EPUB",{"name":738,"fileServerPackageEntryId":738,"fileServerId":739,"fileServerVersionNumber":391,"type":740},"fonc-13-1045817.pdf","1045817/pubmed-zip",{"code":741,"name":741},"PDF",{"name":738,"fileServerPackageEntryId":19,"fileServerId":743,"fileServerVersionNumber":391,"type":744},"1045817/publishers-proof/pdf",{"code":741,"name":741},{"name":746,"fileServerPackageEntryId":746,"fileServerId":739,"fileServerVersionNumber":391,"type":747},"fonc-13-1045817.xml",{"code":748,"name":749},"NLM_XML","XML",{"name":751,"fileServerPackageEntryId":19,"fileServerId":752,"fileServerVersionNumber":391,"type":753},"Provisional PDF.pdf","1045817/provisional-pdf",{"code":741,"name":741},"v3",{"title":756,"link":757,"meta":761,"script":935},"Frontiers | The cancer-risk variant frequency among Polish population reported by the first national whole-genome sequencing study",[758],{"rel":759,"href":760},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/full",[762,765,768,770,773,777,780,784,787,790,793,795,797,799,801,803,806,809,811,814,816,818,821,824,827,830,833,837,841,844,847,850,852,855,857,860,862,865,867,870,872,875,878,881,884,887,890,893,895,898,901,904,906,909,912,915,917,920,922,925,927,930,932],{"hid":763,"property":763,"name":763,"content":764},"description","Population-based cancer screening has raised many controversies in recent years, not only regarding the costs but also of the ethical nature and issues relat...",{"hid":766,"property":766,"name":767,"content":756},"og:title","title",{"hid":769,"property":769,"name":763,"content":764},"og:description",{"hid":771,"name":771,"content":772},"keywords","Genetics,cancer risk,Poland,population cancer screening,Cancer",{"hid":774,"property":774,"name":775,"content":776},"og:site_name","site_name","Frontiers",{"hid":778,"property":778,"name":384,"content":779},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1045817/fonc-13-1045817-HTML/image_m/fonc-13-1045817-g001.jpg",{"hid":781,"property":781,"name":782,"content":783},"og:type","type","article",{"hid":785,"property":785,"name":786,"content":760},"og:url","url",{"hid":788,"name":788,"content":789},"twitter:card","summary_large_image",{"hid":791,"name":791,"content":792},"citation_volume","13",{"hid":794,"name":794,"content":116},"citation_journal_title",{"hid":796,"name":796,"content":776},"citation_publisher",{"hid":798,"name":798,"content":713},"citation_journal_abbrev",{"hid":800,"name":800,"content":714},"citation_issn",{"hid":802,"name":802,"content":536},"citation_doi",{"hid":804,"name":804,"content":805},"citation_firstpage","1045817",{"hid":807,"name":807,"content":808},"citation_language","English",{"hid":810,"name":810,"content":537},"citation_title",{"hid":812,"name":812,"content":813},"citation_keywords","Genetics; cancer risk; Poland; population cancer screening; Cancer",{"hid":815,"name":815,"content":542},"citation_abstract",{"hid":817,"name":817,"content":545},"citation_article_type",{"hid":819,"name":819,"content":820},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/pdf",{"hid":822,"name":822,"content":823},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1045817/xml",{"hid":825,"name":825,"content":826},"citation_fulltext_world_readable","yes",{"hid":828,"name":828,"content":829},"citation_online_date","2023/01/20",{"hid":831,"name":831,"content":832},"citation_publication_date","2023/02/10",{"hid":834,"name":835,"content":836},"citation_author_0","citation_author","Mroczek, Magdalena ",{"hid":838,"name":839,"content":840},"citation_author_institution_0","citation_author_institution","Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw, Poland",{"hid":842,"name":835,"content":843},"citation_author_1","Liu, Jakub ",{"hid":845,"name":839,"content":846},"citation_author_institution_1","Biostatistics Group, Wrocaw University of Environmental and Life Sciences, Poland",{"hid":848,"name":835,"content":849},"citation_author_2","Sypniewski, Mateusz ",{"hid":851,"name":839,"content":840},"citation_author_institution_2",{"hid":853,"name":835,"content":854},"citation_author_3","Piekowski, Tadeusz ",{"hid":856,"name":839,"content":840},"citation_author_institution_3",{"hid":858,"name":835,"content":859},"citation_author_4","Itrych, Bartosz ",{"hid":861,"name":839,"content":840},"citation_author_institution_4",{"hid":863,"name":835,"content":864},"citation_author_5","Stojak, Joanna ",{"hid":866,"name":839,"content":840},"citation_author_institution_5",{"hid":868,"name":835,"content":869},"citation_author_6","Pronobis-Szczylik, Bartosz ",{"hid":871,"name":839,"content":840},"citation_author_institution_6",{"hid":873,"name":835,"content":874},"citation_author_7","Stpie, Maria ",{"hid":876,"name":839,"content":877},"citation_author_institution_7","Department of Sports Medicine, Doctoral School, Medical University of Lublin, Poland",{"hid":879,"name":835,"content":880},"citation_author_8","Kaja, Elbieta ",{"hid":882,"name":839,"content":883},"citation_author_institution_8","Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, Poland",{"hid":885,"name":835,"content":886},"citation_author_9","Dbrowski, Maciej ",{"hid":888,"name":839,"content":889},"citation_author_institution_9","MNM Bioscience Inc., United States",{"hid":891,"name":835,"content":892},"citation_author_10","Suchocki, Tomasz ",{"hid":894,"name":839,"content":846},"citation_author_institution_10",{"hid":896,"name":835,"content":897},"citation_author_11","Wojtaszewska, Marzena ",{"hid":899,"name":839,"content":900},"citation_author_institution_11","Department of Haematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszw, Poland",{"hid":902,"name":835,"content":903},"citation_author_12","Zawadzki, Pawe ",{"hid":905,"name":839,"content":889},"citation_author_institution_12",{"hid":907,"name":835,"content":908},"citation_author_13","Mach, Anna ",{"hid":910,"name":839,"content":911},"citation_author_institution_13","Department of Psychiatry, Medical University of Warsaw, Poland",{"hid":913,"name":835,"content":914},"citation_author_14","Sztromwasser, Pawe ",{"hid":916,"name":839,"content":889},"citation_author_institution_14",{"hid":918,"name":835,"content":919},"citation_author_15","Krl, Zbigniew J. ",{"hid":921,"name":839,"content":840},"citation_author_institution_15",{"hid":923,"name":835,"content":924},"citation_author_16","Szyda, Joanna ",{"hid":926,"name":839,"content":846},"citation_author_institution_16",{"hid":928,"name":835,"content":929},"citation_author_17","Dobosz, Paula ",{"hid":931,"name":839,"content":840},"citation_author_institution_17",{"hid":933,"name":933,"content":934},"dc.identifier","doi:10.3389/fonc.2023.1045817",[936,939,941,943,945],{"src":937,"body":13,"type":938,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":940,"body":13,"type":938,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":942,"body":13,"type":938,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":944,"body":13,"type":938,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1045817?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":946,"body":13,"type":938,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":948,"articleHubArticlesList":949,"canJournalHasArticleHub":367,"articleDoiList":950},{},[],[],{"title":19,"image":-1,"breadcrumbs":952,"linksCollection":953,"metricsCollection":955},[],{"total":388,"items":954},[],{"total":388,"items":956},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1045817?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>